The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Tumors or cancer of the human BREAST.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Antimetabolites that are useful in cancer chemotherapy.
Tumors or cancer of the LUNG.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
An organoplatinum compound that possesses antineoplastic activity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Elements of limited time intervals, contributing to particular results or situations.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
A cell line derived from cultured tumor cells.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Organic compounds which contain platinum as an integral part of the molecule.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A malignant epithelial tumor with a glandular organization.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A decrease in the number of NEUTROPHILS found in the blood.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
An alkylating agent of value against both hematologic malignancies and solid tumors.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Transplantation of an individual's own tissue from one site to another site.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
An anthracenedione-derived antineoplastic agent.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Clinical protocols used to inhibit the growth or spread of NEOPLASMS.
Tumors or cancer of the LIVER.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
A general term for various neoplastic diseases of the lymphoid tissue.
A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Tumors or cancer of the COLON.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A group of 20-member macrolactones in which there are three remotely substituted pyran rings that are linked by a methylene bridge and an E-disubstituted alkene, and have geminal dimethyls at C8 and C18 carbons. Some interact with PROTEIN KINASE C.
Pyrido-CARBAZOLES originally discovered in the bark of OCHROSIA ELLIPTICA. They inhibit DNA and RNA synthesis and have immunosuppressive properties.
Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Antibodies produced by a single clone of cells.
The return of a sign, symptom, or disease after a remission.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
Inorganic compounds which contain platinum as the central atom.
Coverings for the hands, usually with separations for the fingers, made of various materials, for protection against infections, toxic substances, extremes of hot and cold, radiations, water immersion, etc. The gloves may be worn by patients, care givers, housewives, laboratory and industrial workers, police, etc.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Simultaneous resistance to several structurally and functionally distinct drugs.
A nursing specialty concerned with the care provided to cancer patients. It includes aspects of family functioning through education of both patient and family.
Drugs used to prevent NAUSEA or VOMITING.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Tumors or cancer of the PERITONEUM.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
A subnormal level of BLOOD PLATELETS.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Tumors or cancer of the STOMACH.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
Alkaloids derived from TYRAMINE combined with 3,4-dihydroxybenzaldehyde via a norbelladine pathway, including GALANTAMINE, lycorine and crinine. They are found in the Amaryllidaceae (LILIACEAE) plant family.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A plant genus of the family LILIACEAE. Members contain ungiminorine and LECTINS.
A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
A plant genus of the family ASTERACEAE. This plant should not be confused with microtubule asters (MICROTUBULES) nor with aster yellows phytoplasma (mycoplasma-like organisms).
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
A plan for collecting and utilizing data so that desired information can be obtained with sufficient precision or so that an hypothesis can be tested properly.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
An anti-inflammatory 9-fluoro-glucocorticoid.
The giving of drugs, chemicals, or other substances by mouth.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).
Compounds with 1,2-diphenylethane. They are structurally like reduced STILBENES.
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
Treatment that combines chemotherapy with radiotherapy.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
A small plant family of the order Santalales, subclass Rosidae, class Magnoliopsida.
Cyclic hydrocarbons that contain multiple rings and share one or more atoms.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Individuals responsible for various duties pertaining to the medical office routine.
The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.
A subspecialty of internal medicine concerned with the study of neoplasms.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Tumors or cancer of the PROSTATE.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Proteins prepared by recombinant DNA technology.
Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES.
Devices designed to provide personal protection against injury to individuals exposed to hazards in industry, sports, aviation, or daily activities.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Antagonist of urate oxidase.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Functions and activities of DENTITION as a whole.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Antibodies obtained from a single clone of cells grown in mice or rats.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.

Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/20433)

Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients.  (+info)

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2/20433)

Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0-26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer.  (+info)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (3/20433)

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.  (+info)

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (4/20433)

Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency.  (+info)

Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study. (5/20433)

We report a population-based study of patterns of care and survival for people with acute leukaemia diagnosed at age 15-29 years during 1984-94 in regions of England and Wales covered by specialist leukaemia registries. There were 879 patients: 417 with acute lymphoblastic leukaemia (ALL) and 462 with acute myeloid leukaemia (AML). For ALL, actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Patients entered in national clinical trials and those not entered had similar survival rates. Survival rates were similar at teaching and non-teaching hospitals and at hospitals treating different numbers of study patients per year. For AML, survival rates were 42% at 5 years after diagnosis and 39% at 10 years. Survival improved significantly between 1984-88 and 1989-94. Patients entered in the Medical Research Council AML10 trial had a higher survival rate than those who were in the earlier AML9 trial. Survival did not vary with category of hospital. We conclude that survival has improved for adolescents and young adults with acute leukaemia but that there is at present no evidence that centralized treatment results in a survival benefit for patients in this age group.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (6/20433)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (7/20433)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (8/20433)

Current guidelines for the treatment of catheter-related bacteraemia (CRB) advise against central venous catheter (CVC) exchange because of the potential risk of prolonging infection. However, there are no consistent data proving this recommendation. We evaluated prospectively the usefulness of CVC exchange by guidewire for the treatment of CRB in patients undergoing BMT or intensive chemotherapy. CVC exchange was considered when fever and positive blood cultures persisted after 2 days of adequate antimicrobial therapy and no potential source of bacteraemia other than CVC could be identified. The guidewire exchange was preceded and followed by a slow infusion of adequate antimicrobial therapy. Bacteraemia was confirmed as catheter-related by demonstrating concordance between isolates from the tip and blood cultures by pulsed-field electrophoresis of genomic DNA. This procedure was performed in 19 episodes of bacteraemia during a 1-year period. Fourteen episodes (74%) were catheter-related and 71% of these were due to coagulase-negative staphylococci. Guidewire replacement was accomplished uneventfully 4 days after development of sepsis (range 3-6). In all cases, clinical signs of sepsis disappeared in less than 24 h after replacement. Definitive catheter withdrawal was carried out a median of 16 days (range 3-42) after guidewire exchange; in all cases, the tip culture was negative. We conclude that CVC replacement by guidewire under adequate antimicrobial therapy may be a reasonable option for the treatment of CRB when antimicrobial therapy alone has been unsuccessful.  (+info)

There are several types of osteosarcomas, including:

1. High-grade osteosarcoma: This is the most common type of osteosarcoma and tends to grow quickly.
2. Low-grade osteosarcoma: This type of osteosarcoma grows more slowly than high-grade osteosarcoma.
3. Chondrosarcoma: This is a type of osteosarcoma that arises in the cartilage cells of the bone.
4. Ewing's family of tumors: These are rare types of osteosarcoma that can occur in any bone of the body.

The exact cause of osteosarcoma is not known, but certain risk factors may increase the likelihood of developing the disease. These include:

1. Previous radiation exposure
2. Paget's disease of bone
3. Li-Fraumeni syndrome (a genetic disorder that increases the risk of certain types of cancer)
4. Familial retinoblastoma (a rare inherited condition)
5. Exposure to certain chemicals, such as herbicides and industrial chemicals.

Symptoms of osteosarcoma may include:

1. Pain in the affected bone, which may be worse at night or with activity
2. Swelling and redness around the affected area
3. Limited mobility or stiffness in the affected limb
4. A visible lump or mass on the affected bone
5. Fractures or breaks in the affected bone

If osteosarcoma is suspected, a doctor may perform several tests to confirm the diagnosis and determine the extent of the disease. These may include:

1. Imaging studies, such as X-rays, CT scans, or MRI scans
2. Biopsy, in which a sample of tissue is removed from the affected bone and examined under a microscope for cancer cells
3. Blood tests to check for elevated levels of certain enzymes that are produced by osteosarcoma cells
4. Bone scans to look for areas of increased activity or metabolism in the bones.

Pre-B ALL is characterized by the abnormal growth of immature white blood cells called B lymphocytes. These cells are produced in the bone marrow and are normally present in the blood. In Pre-B ALL, the abnormal B cells accumulate in the bone marrow, blood, and other organs, crowding out normal cells and causing a variety of symptoms.

The symptoms of Pre-B ALL can vary depending on the individual patient, but may include:

* Fatigue
* Easy bruising or bleeding
* Frequent infections
* Swollen lymph nodes
* Enlarged liver or spleen
* Bone pain
* Headaches
* Confusion or seizures (in severe cases)

Pre-B ALL is most commonly diagnosed in children, but it can also occur in adults. Treatment typically involves a combination of chemotherapy and sometimes bone marrow transplantation. The prognosis for Pre-B ALL is generally good, especially in children, with a high survival rate if treated promptly and effectively. However, the cancer can be more difficult to treat in adults, and the prognosis may be less favorable.

Overall, Pre-B ALL is a rare and aggressive form of leukemia that requires prompt and specialized treatment to improve outcomes for patients.

There are different types of Breast Neoplasms such as:

1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.

2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.

3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.

4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.

5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.

Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.

Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.

It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

There are several types of lung neoplasms, including:

1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.

Lung diseases can also be classified based on their cause, such as:

1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.

Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

Benign ovarian neoplasms include:

1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.

Malignant ovarian neoplasms include:

1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.

Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.

Neoplastic metastasis can occur in any type of cancer but are more common in solid tumors such as carcinomas (breast, lung, colon). It is important for cancer diagnosis and prognosis because metastasis indicates that the cancer has spread beyond its original site and may be more difficult to treat.

Metastases can appear at any distant location but commonly found sites include the liver, lungs, bones, brain, and lymph nodes. The presence of metastases indicates a higher stage of cancer which is associated with lower survival rates compared to localized cancer.

Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:

1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)

The symptoms of adenocarcinoma depend on the location of the cancer and can include:

1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)

The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.

Treatment options for adenocarcinoma depend on the location of the cancer and can include:

1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.

The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.

Adenocarcinoma is the most common subtype of NSCLC and is characterized by malignant cells that have glandular or secretory properties. Squamous cell carcinoma is less common and is characterized by malignant cells that resemble squamous epithelium. Large cell carcinoma is a rare subtype and is characterized by large, poorly differentiated cells.

The main risk factor for developing NSCLC is tobacco smoking, which is responsible for approximately 80-90% of all cases. Other risk factors include exposure to secondhand smoke, radon gas, asbestos, and certain chemicals in the workplace or environment.

Symptoms of NSCLC can include coughing, chest pain, shortness of breath, and fatigue. The diagnosis is typically made through a combination of imaging studies such as CT scans, PET scans, and biopsy. Treatment options for NSCLC can include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for NSCLC depends on several factors, including the stage of the cancer, the patient's overall health, and the effectiveness of treatment.

Overall, NSCLC is a common and aggressive form of lung cancer that can be treated with a variety of therapies. Early detection and treatment are critical for improving outcomes in patients with this diagnosis.

Vomiting can be caused by a variety of factors, such as:

1. Infection: Viral or bacterial infections can inflame the stomach and intestines, leading to vomiting.
2. Food poisoning: Consuming contaminated or spoiled food can cause vomiting.
3. Motion sickness: Traveling by car, boat, plane, or other modes of transportation can cause motion sickness, which leads to vomiting.
4. Alcohol or drug overconsumption: Drinking too much alcohol or taking certain medications can irritate the stomach and cause vomiting.
5. Pregnancy: Hormonal changes during pregnancy can cause nausea and vomiting, especially during the first trimester.
6. Other conditions: Vomiting can also be a symptom of other medical conditions such as appendicitis, pancreatitis, and migraines.

When someone is vomiting, they may experience:

1. Nausea: A feeling of queasiness or sickness in the stomach.
2. Abdominal pain: Crampy or sharp pain in the abdomen.
3. Diarrhea: Loose, watery stools.
4. Dehydration: Loss of fluids and electrolytes.
5. Headache: A throbbing headache can occur due to dehydration.
6. Fatigue: Weakness and exhaustion.

Treatment for vomiting depends on the underlying cause, but may include:

1. Fluid replacement: Drinking fluids to replenish lost electrolytes and prevent dehydration.
2. Medications: Anti-inflammatory drugs or antibiotics may be prescribed to treat infections or other conditions causing vomiting.
3. Rest: Resting the body and avoiding strenuous activities.
4. Dietary changes: Avoiding certain foods or substances that trigger vomiting.
5. Hospitalization: In severe cases of vomiting, hospitalization may be necessary to monitor and treat underlying conditions.

It is important to seek medical attention if the following symptoms occur with vomiting:

1. Severe abdominal pain.
2. Fever above 101.5°F (38.6°C).
3. Blood in vomit or stools.
4. Signs of dehydration, such as excessive thirst, dark urine, or dizziness.
5. Vomiting that lasts for more than 2 days.
6. Frequent vomiting with no relief.

In medical terminology, nausea is sometimes used interchangeably with the term "dyspepsia," which refers to a general feeling of discomfort or unease in the stomach, often accompanied by symptoms such as bloating, belching, or heartburn. However, while nausea and dyspepsia can be related, they are not always the same thing, and it's important to understand the specific underlying cause of any gastrointestinal symptoms in order to provide appropriate treatment.

Some common causes of nausea include:

* Gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastritis
* Motion sickness or seasickness
* Medication side effects, including chemotherapy drugs, antibiotics, and painkillers
* Pregnancy and morning sickness
* Food poisoning or other infections
* Migraines and other headaches
* Anxiety and stress

Treatment for nausea will depend on the underlying cause, but may include medications such as antihistamines, anticholinergics, or anti-nausea drugs, as well as non-pharmacological interventions such as ginger, acupressure, or relaxation techniques. In severe cases, hospitalization may be necessary to manage symptoms and prevent dehydration or other complications.

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

The causes of colorectal neoplasms are not fully understood, but factors such as age, genetics, diet, and lifestyle have been implicated. Symptoms of colorectal cancer can include changes in bowel habits, blood in the stool, abdominal pain, and weight loss. Screening for colorectal cancer is recommended for adults over the age of 50, as it can help detect early-stage tumors and improve survival rates.

There are several subtypes of colorectal neoplasms, including adenomas (which are precancerous polyps), carcinomas (which are malignant tumors), and lymphomas (which are cancers of the immune system). Treatment options for colorectal cancer depend on the stage and location of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Research into the causes and treatment of colorectal neoplasms is ongoing, and there has been significant progress in recent years. Advances in screening and treatment have improved survival rates for patients with colorectal cancer, and there is hope that continued research will lead to even more effective treatments in the future.

Symptoms of neutropenia may include recurring infections, fever, fatigue, weight loss, and swollen lymph nodes. The diagnosis is typically made through a blood test that measures the number of neutrophils in the blood.

Treatment options for neutropenia depend on the underlying cause but may include antibiotics, supportive care to manage symptoms, and in severe cases, bone marrow transplantation or granulocyte-colony stimulating factor (G-CSF) therapy to increase neutrophil production.

Brain neoplasms can arise from various types of cells in the brain, including glial cells (such as astrocytes and oligodendrocytes), neurons, and vascular tissues. The symptoms of brain neoplasms vary depending on their size, location, and type, but may include headaches, seizures, weakness or numbness in the limbs, and changes in personality or cognitive function.

There are several different types of brain neoplasms, including:

1. Meningiomas: These are benign tumors that arise from the meninges, the thin layers of tissue that cover the brain and spinal cord.
2. Gliomas: These are malignant tumors that arise from glial cells in the brain. The most common type of glioma is a glioblastoma, which is aggressive and hard to treat.
3. Pineal parenchymal tumors: These are rare tumors that arise in the pineal gland, a small endocrine gland in the brain.
4. Craniopharyngiomas: These are benign tumors that arise from the epithelial cells of the pituitary gland and the hypothalamus.
5. Medulloblastomas: These are malignant tumors that arise in the cerebellum, specifically in the medulla oblongata. They are most common in children.
6. Acoustic neurinomas: These are benign tumors that arise on the nerve that connects the inner ear to the brain.
7. Oligodendrogliomas: These are malignant tumors that arise from oligodendrocytes, the cells that produce the fatty substance called myelin that insulates nerve fibers.
8. Lymphomas: These are cancers of the immune system that can arise in the brain and spinal cord. The most common type of lymphoma in the CNS is primary central nervous system (CNS) lymphoma, which is usually a type of B-cell non-Hodgkin lymphoma.
9. Metastatic tumors: These are tumors that have spread to the brain from another part of the body. The most common types of metastatic tumors in the CNS are breast cancer, lung cancer, and melanoma.

These are just a few examples of the many types of brain and spinal cord tumors that can occur. Each type of tumor has its own unique characteristics, such as its location, size, growth rate, and biological behavior. These factors can help doctors determine the best course of treatment for each patient.

Some common types of bone neoplasms include:

* Osteochondromas: These are benign tumors that grow on the surface of a bone.
* Giant cell tumors: These are benign tumors that can occur in any bone of the body.
* Chondromyxoid fibromas: These are rare, benign tumors that develop in the cartilage of a bone.
* Ewing's sarcoma: This is a malignant tumor that usually occurs in the long bones of the arms and legs.
* Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow.

Symptoms of bone neoplasms can include pain, swelling, or deformity of the affected bone, as well as weakness or fatigue. Treatment options depend on the type and location of the tumor, as well as the severity of the symptoms. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these.

Testicular neoplasms refer to abnormal growths or tumors that develop in the testicles, which are located inside the scrotum. These tumors can be benign (non-cancerous) or malignant (cancerous). Testicular neoplasms can affect men of all ages, but they are more common in younger men between the ages of 20 and 35.

Types of Testicular Neoplasms:

There are several types of testicular neoplasms, including:

1. Seminoma: This is a type of malignant tumor that develops from immature cells in the testicles. It is the most common type of testicular cancer and tends to grow slowly.
2. Non-seminomatous germ cell tumors (NSGCT): These are malignant tumors that develop from immature cells in the testicles, but they do not have the characteristic features of seminoma. They can be either heterologous (containing different types of cells) or homologous (containing only one type of cell).
3. Leydig cell tumors: These are rare malignant tumors that develop in the Leydig cells, which produce testosterone in the testicles.
4. Sertoli cell tumors: These are rare malignant tumors that develop in the Sertoli cells, which support the development of sperm in the testicles.
5. Testicular metastasectomy: This is a procedure to remove cancer that has spread to the testicles from another part of the body, such as the lungs or liver.

Causes and Risk Factors:

The exact cause of testicular neoplasms is not known, but there are several risk factors that have been linked to an increased risk of developing these tumors. These include:

1. Undescended testicles (cryptorchidism): This condition occurs when the testicles do not descend into the scrotum during fetal development.
2. Family history: Men with a family history of testicular cancer are at an increased risk of developing these tumors.
3. Previous radiation exposure: Men who have had radiation therapy to the pelvic area, especially during childhood or adolescence, have an increased risk of developing testicular neoplasms.
4. Genetic mutations: Certain genetic mutations, such as those associated with familial testicular cancer syndrome, can increase the risk of developing testicular neoplasms.
5. Infertility: Men who are infertile may have an increased risk of developing testicular cancer.

Symptoms:

The symptoms of testicular neoplasms can vary depending on the type and location of the tumor. Some common symptoms include:

1. A lump or swelling in the testicle
2. Pain or discomfort in the testicle or scrotum
3. Enlargement of the testicle
4. Abnormality in the size or shape of the testicle
5. Pain during ejaculation
6. Difficulty urinating or painful urination
7. Breast tenderness or enlargement
8. Lower back pain
9. Fatigue
10. Weight loss

Diagnosis:

The diagnosis of testicular neoplasms typically involves a combination of physical examination, imaging studies, and biopsy.

1. Physical examination: A doctor will perform a thorough physical examination of the testicles, including checking for any abnormalities in size, shape, or tenderness.
2. Imaging studies: Imaging studies such as ultrasound, CT scans, or MRI may be used to help identify the location and extent of the tumor.
3. Biopsy: A biopsy is a procedure in which a small sample of tissue is removed from the testicle and examined under a microscope for cancer cells.
4. Blood tests: Blood tests may be performed to check for elevated levels of certain substances that can indicate the presence of cancer.

Treatment:

The treatment of testicular neoplasms depends on the type, location, and stage of the tumor. Some common treatments include:

1. Surgery: Surgery is often the first line of treatment for testicular neoplasms. The goal of surgery is to remove the tumor and any affected tissue.
2. Chemotherapy: Chemotherapy may be used in combination with surgery or radiation therapy to treat more advanced cancers.
3. Radiation therapy: Radiation therapy uses high-energy beams to kill cancer cells. It may be used in combination with surgery or chemotherapy.
4. Surveillance: Surveillance is a close monitoring of the patient's condition, including regular check-ups and imaging studies, to detect any recurrences of the tumor.

Prognosis:

The prognosis for testicular neoplasms depends on the type, location, and stage of the tumor. In general, the earlier the cancer is detected and treated, the better the prognosis. Some common types of testicular neoplasms have a good prognosis, while others are more aggressive and may have a poorer prognosis if not treated promptly.

Complications:

Some complications of testicular neoplasms include:

1. Recurrence: The cancer can recur in the testicle or spread to other parts of the body.
2. Spread to other parts of the body: Testicular cancer can spread to other parts of the body, such as the lungs, liver, or brain.
3. Infertility: Some treatments for testicular cancer, such as chemotherapy and radiation therapy, can cause infertility.
4. Hormone imbalance: Some types of testicular cancer can disrupt hormone levels, leading to symptoms such as breast enlargement or low sex drive.
5. Chronic pain: Some men may experience chronic pain in the testicle or scrotum after treatment for testicular cancer.

Lifestyle changes:

There are no specific lifestyle changes that can prevent testicular neoplasms, but some general healthy habits can help reduce the risk of developing these types of tumors. These include:

1. Maintaining a healthy weight and diet
2. Getting regular exercise
3. Limiting alcohol consumption
4. Avoiding smoking and recreational drugs
5. Protecting the testicles from injury or trauma

Screening:

There is no standard screening test for testicular neoplasms, but men can perform a self-exam to check for any abnormalities in their testicles. This involves gently feeling the testicles for any lumps or unusual texture. Men with a family history of testicular cancer should talk to their doctor about whether they should start screening earlier and more frequently.

Treatment:

The treatment of testicular neoplasms depends on the type, stage, and location of the tumor. Some common treatments include:

1. Surgery: This involves removing the affected testicle or tumor.
2. Chemotherapy: This involves using drugs to kill cancer cells.
3. Radiation therapy: This involves using high-energy rays to kill cancer cells.
4. Hormone therapy: This involves taking medications to alter hormone levels and slow the growth of cancer cells.
5. Clinical trials: These involve testing new treatments or combination of treatments for testicular neoplasms.

Prognosis:

The prognosis for testicular neoplasms varies depending on the type, stage, and location of the tumor. In general, the earlier the cancer is detected and treated, the better the prognosis. For example, seminoma has a high cure rate with current treatments, while non-seminomatous germ cell tumors have a lower cure rate but can still be effectively treated. Lymphoma and metastatic testicular cancer have a poorer prognosis and require aggressive treatment.

Lifestyle Changes:

There are no specific lifestyle changes that can prevent testicular neoplasms, but some risk factors such as smoking and alcohol consumption can be reduced to lower the risk of developing these tumors. Maintaining a healthy diet, regular exercise, and avoiding exposure to harmful chemicals can also help improve overall health and well-being.

Complications:

Testicular neoplasms can have several complications, including:

1. Infertility: Some treatments for testicular cancer, such as surgery or chemotherapy, can cause infertility.
2. Pain: Testicular cancer can cause pain in the scrotum, groin, or abdomen.
3. Swelling: Testicular cancer can cause swelling in the scrotum or groin.
4. Hormonal imbalance: Some testicular tumors can produce hormones that can cause an imbalance in the body's hormone levels.
5. Recurrence: Testicular cancer can recur after treatment, and regular follow-up is necessary to detect any signs of recurrence early.
6. Late effects of treatment: Some treatments for testicular cancer, such as chemotherapy, can have long-term effects on the body, including infertility, heart problems, and bone marrow suppression.
7. Metastasis: Testicular cancer can spread to other parts of the body, including the lungs, liver, and bones, which can be life-threatening.

Prevention:

There is no specific prevention for testicular neoplasms, but some risk factors such as undescended testes, family history, and exposure to certain chemicals can be reduced to lower the risk of developing these tumors. Regular self-examination and early detection are crucial in improving outcomes for patients with testicular cancer.

Conclusion:

Testicular neoplasms are a rare but potentially life-threatening condition that requires prompt and accurate diagnosis and treatment. Early detection through regular self-examination and follow-up can improve outcomes, while awareness of risk factors and symptoms is essential in reducing the burden of this disease. A multidisciplinary approach involving urologists, radiologists, pathologists, and oncologists is necessary for optimal management of patients with testicular neoplasms.

White blood cells are an important part of the immune system, and they help to fight off infections and diseases. A low number of white blood cells can make a person more susceptible to infections and other health problems.

There are several different types of leukopenia, including:

* Severe congenital neutropenia: This is a rare genetic disorder that causes a severe decrease in the number of neutrophils, a type of white blood cell.
* Chronic granulomatous disease: This is a genetic disorder that affects the production of white blood cells and can cause recurring infections.
* Autoimmune disorders: These are conditions where the immune system mistakenly attacks its own cells, including white blood cells. Examples include lupus and rheumatoid arthritis.
* Bone marrow failure: This is a condition where the bone marrow does not produce enough white blood cells, red blood cells, or platelets.

Symptoms of leukopenia can include recurring infections, fever, fatigue, and weight loss. Treatment depends on the underlying cause of the condition and may include antibiotics, immunoglobulin replacement therapy, or bone marrow transplantation.

In the medical field, Leukemia P388 is defined as a subline of leukemia cells that exhibits a specific set of genetic alterations and characteristics, including the ability to grow and proliferate in culture and in vivo, resistance to certain drugs and therapies, and the presence of specific markers and mutations.

Leukemia P388 is commonly used in research to study the biology of leukemia and to develop new treatments for this disease. It is also sometimes used as a model to study other types of cancer, such as lymphoma and solid tumors.

Overall, Leukemia P388 is an important tool in the study of cancer biology and is used to advance our understanding of the disease and to develop new treatments for patients with leukemia and other types of cancer.

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.

There are several types of liver neoplasms, including:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.

The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.

Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.

Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

There are several types of colonic neoplasms, including:

1. Adenomas: These are benign growths that are usually precursors to colorectal cancer.
2. Carcinomas: These are malignant tumors that arise from the epithelial lining of the colon.
3. Sarcomas: These are rare malignant tumors that arise from the connective tissue of the colon.
4. Lymphomas: These are cancers of the immune system that can affect the colon.

Colonic neoplasms can cause a variety of symptoms, including bleeding, abdominal pain, and changes in bowel habits. They are often diagnosed through a combination of medical imaging tests (such as colonoscopy or CT scan) and biopsy. Treatment for colonic neoplasms depends on the type and stage of the tumor, and may include surgery, chemotherapy, and/or radiation therapy.

Overall, colonic neoplasms are a common condition that can have serious consequences if left untreated. It is important for individuals to be aware of their risk factors and to undergo regular screening for colon cancer to help detect and treat any abnormal growths or tumors in the colon.

SCC typically appears as a firm, flat, or raised bump on the skin, and may be pink, red, or scaly. The cancer cells are usually well-differentiated, meaning they resemble normal squamous cells, but they can grow rapidly and invade surrounding tissues if left untreated.

SCC is more common in fair-skinned individuals and those who spend a lot of time in the sun, as UV radiation can damage the skin cells and increase the risk of cancer. The cancer can also spread to other parts of the body, such as lymph nodes or organs, and can be life-threatening if not treated promptly and effectively.

Treatment for SCC usually involves surgery to remove the cancerous tissue, and may also include radiation therapy or chemotherapy to kill any remaining cancer cells. Early detection and treatment are important to improve outcomes for patients with SCC.

Examples of neoplasms, germ cell and embryonal include:

1. Testicular cancer: This type of cancer develops in the cells of the testes and is most common in young men between the ages of 20 and 35.
2. Ovarian cancer: This type of cancer develops in the cells of the ovaries and is most common in older women.
3. Embryonal carcinoma: This type of cancer develops in the cells that form the embryo during fetal development. It is rare and tends to affect children and young adults.
4. Teratocarcinoma: This type of cancer develops in the cells that form the placenta during pregnancy. It is rare and tends to affect women who have abnormal pregnancies.

Neoplasms, germ cell and embryonal are typically treated with surgery, chemotherapy, or radiation therapy, depending on the location and severity of the cancer. The prognosis for these types of cancers is generally good if they are detected early and treated appropriately. However, if they are not diagnosed and treated promptly, they can spread to other parts of the body and be more difficult to treat.

There are several subtypes of carcinoma, including:

1. Adenocarcinoma: This type of carcinoma originates in glandular cells, which produce fluids or mucus. Examples include breast cancer, prostate cancer, and colon cancer.
2. Squamous cell carcinoma: This type of carcinoma originates in squamous cells, which are found on the surface layers of skin and mucous membranes. Examples include head and neck cancers, cervical cancer, and anal cancer.
3. Basal cell carcinoma: This type of carcinoma originates in the deepest layer of skin, called the basal layer. It is the most common type of skin cancer and tends to grow slowly.
4. Neuroendocrine carcinoma: This type of carcinoma originates in cells that produce hormones and neurotransmitters. Examples include lung cancer, pancreatic cancer, and thyroid cancer.
5. Small cell carcinoma: This type of carcinoma is a highly aggressive form of lung cancer that spreads quickly to other parts of the body.

The signs and symptoms of carcinoma depend on the location and stage of the cancer. Some common symptoms include:

* A lump or mass
* Pain
* Skin changes, such as a new mole or a change in the color or texture of the skin
* Changes in bowel or bladder habits
* Abnormal bleeding

The diagnosis of carcinoma typically involves a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue for examination under a microscope. Treatment options for carcinoma depend on the location and stage of the cancer and may include surgery, radiation therapy, chemotherapy, or a combination of these.

In conclusion, carcinoma is a type of cancer that originates in epithelial cells and can occur in various parts of the body. Early detection and treatment are important for improving outcomes.

References:

1. American Cancer Society. (2022). Carcinoma. Retrieved from
2. Mayo Clinic. (2022). Carcinoma. Retrieved from
3. MedlinePlus. (2022). Carcinoma. Retrieved from

Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.

In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.

AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.

There are several subtypes of AML, including:

1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.

The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:

* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures

AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:

1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.

Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:

1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.

It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Peritoneal neoplasms are relatively rare, but they can be aggressive and difficult to treat. The most common types of peritoneal neoplasms include:

1. Peritoneal mesothelioma: This is the most common type of peritoneal neoplasm and arises from the mesothelial cells that line the abdominal cavity. It is often associated with asbestos exposure.
2. Ovarian cancer: This type of cancer originates in the ovaries and can spread to the peritoneum.
3. Appendiceal cancer: This type of cancer arises in the appendix and can spread to the peritoneum.
4. Pseudomyxoma peritonei: This is a rare type of cancer that originates in the abdominal cavity and resembles a mucin-secreting tumor.
5. Primary peritoneal cancer: This type of cancer originates in the peritoneum itself and can be of various types, including adenocarcinoma, squamous cell carcinoma, and sarcoma.

The symptoms of peritoneal neoplasms vary depending on the location and size of the tumor, but may include abdominal pain, distension, and difficulty eating or passing stool. Treatment options for peritoneal neoplasms depend on the type and stage of the cancer, but may include surgery, chemotherapy, and radiation therapy. Prognosis for peritoneal neoplasms is generally poor, with a five-year survival rate of around 20-30%.

There are several possible causes of thrombocytopenia, including:

1. Immune-mediated disorders such as idiopathic thrombocytopenic purpura (ITP) or systemic lupus erythematosus (SLE).
2. Bone marrow disorders such as aplastic anemia or leukemia.
3. Viral infections such as HIV or hepatitis C.
4. Medications such as chemotherapy or non-steroidal anti-inflammatory drugs (NSAIDs).
5. Vitamin deficiencies, especially vitamin B12 and folate.
6. Genetic disorders such as Bernard-Soulier syndrome.
7. Sepsis or other severe infections.
8. Disseminated intravascular coagulation (DIC), a condition where blood clots form throughout the body.
9. Postpartum thrombocytopenia, which can occur in some women after childbirth.

Symptoms of thrombocytopenia may include easy bruising, petechiae (small red or purple spots on the skin), and prolonged bleeding from injuries or surgical sites. Treatment options depend on the underlying cause but may include platelet transfusions, steroids, immunosuppressive drugs, and in severe cases, surgery.

In summary, thrombocytopenia is a condition characterized by low platelet counts that can increase the risk of bleeding and bruising. It can be caused by various factors, and treatment options vary depending on the underlying cause.

Lymphatic metastasis occurs when cancer cells enter the lymphatic vessels and are carried through the lymphatic system to other parts of the body. This can happen through several mechanisms, including:

1. Direct invasion: Cancer cells can invade the nearby lymphatic vessels and spread through them.
2. Lymphatic vessel embolization: Cancer cells can block the flow of lymphatic fluid and cause the formation of a clot-like structure, which can trap cancer cells and allow them to grow.
3. Lymphatic vessel invasion: Cancer cells can infiltrate the walls of lymphatic vessels and spread through them.

Lymphatic metastasis is a common mechanism for the spread of cancer, particularly in the breast, melanoma, and other cancers that have a high risk of lymphatic invasion. The presence of lymphatic metastasis in a patient's body can indicate a more aggressive cancer and a poorer prognosis.

Treatment for lymphatic metastasis typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery may be used to remove any affected lymph nodes or other tumors that have spread through the lymphatic system. Chemotherapy may be used to kill any remaining cancer cells, while radiation therapy may be used to shrink the tumors and relieve symptoms.

In summary, lymphatic metastasis is a common mechanism for the spread of cancer through the body, particularly in cancers that originate in organs with a high lymphatic drainage. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy to remove or shrink the tumors and relieve symptoms.

There are several types of stomach neoplasms, including:

1. Adenocarcinoma: This is the most common type of stomach cancer, accounting for approximately 90% of all cases. It begins in the glandular cells that line the stomach and can spread to other parts of the body.
2. Squamous cell carcinoma: This type of cancer begins in the squamous cells that cover the outer layer of the stomach. It is less common than adenocarcinoma but more likely to be found in the upper part of the stomach.
3. Gastric mixed adenocarcinomasquamous cell carcinoma: This type of cancer is a combination of adenocarcinoma and squamous cell carcinoma.
4. Lymphoma: This is a cancer of the immune system that can occur in the stomach. It is less common than other types of stomach cancer but can be more aggressive.
5. Carcinomas of the stomach: These are malignant tumors that arise from the epithelial cells lining the stomach. They can be subdivided into adenocarcinoma, squamous cell carcinoma, and others.
6. Gastric brunner's gland adenoma: This is a rare type of benign tumor that arises from the Brunner's glands in the stomach.
7. Gastric polyps: These are growths that occur on the lining of the stomach and can be either benign or malignant.

The symptoms of stomach neoplasms vary depending on the location, size, and type of tumor. Common symptoms include abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. Diagnosis is usually made through a combination of endoscopy, imaging studies (such as CT or PET scans), and biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for stomach neoplasms varies depending on the type and stage of the tumor, but early detection and treatment can improve outcomes.

Germinomas are rare and account for only about 1% to 3% of all germ cell tumors. They are more common in children and young adults, and the median age at diagnosis is around 10 to 20 years. These tumors tend to grow slowly and may not cause any symptoms in their early stages.

The signs and symptoms of germinoma can vary depending on the location and size of the tumor. In general, they may include:

* Abdominal pain or discomfort
* Swelling or lump in the abdomen
* Vaginal bleeding or discharge in females
* Painful urination or scrotal swelling in males
* Fatigue or fever

If a germinoma is suspected, imaging tests such as CT scans, MRI scans, or ultrasound may be ordered to confirm the diagnosis. A biopsy may also be performed to examine the tumor cells under a microscope.

Treatment for germinoma typically involves surgery to remove the tumor and any affected tissues. In some cases, chemotherapy or radiation therapy may be recommended to ensure that all cancerous cells are eliminated. The prognosis for germinoma is generally good, with a five-year survival rate of around 90% for children and young adults. However, the tumor can recur in some cases, so follow-up care is important.

In summary, germinoma is a rare type of tumor that originates from germ cells in the reproductive system. It can be benign or malignant and tends to grow slowly, causing abdominal pain, swelling, or other symptoms. Treatment typically involves surgery and may include chemotherapy or radiation therapy, with a good prognosis for most patients.

Some common types of head and neck neoplasms include:

1. Oral cavity cancer: Cancer that develops in the mouth, tongue, lips, or floor of the mouth.
2. Oropharyngeal cancer: Cancer that develops in the throat, including the base of the tongue, soft palate, and tonsils.
3. Hypopharyngeal cancer: Cancer that develops in the lower part of the throat, near the esophagus.
4. Laryngeal cancer: Cancer that develops in the voice box (larynx).
5. Paranasal sinus cancer: Cancer that develops in the air-filled cavities around the eyes and nose.
6. Salivary gland cancer: Cancer that develops in the salivary glands, which produce saliva to moisten food and keep the mouth lubricated.
7. Thyroid gland cancer: Cancer that develops in the butterfly-shaped gland in the neck that regulates metabolism and growth.

The risk factors for developing head and neck neoplasms include tobacco use, heavy alcohol consumption, human papillomavirus (HPV) infection, poor diet, and exposure to environmental carcinogens such as asbestos or radiation. Symptoms of head and neck neoplasms can vary depending on the location and size of the tumor, but may include a lump or swelling, pain, difficulty swallowing, bleeding, and changes in voice or breathing.

Diagnosis of head and neck neoplasms typically involves a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy to confirm the presence of cancer cells. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, depending on the type, location, and stage of the cancer.

Overall, head and neck neoplasms can have a significant impact on quality of life, and early detection and treatment are important for improving outcomes. If you suspect any changes in your head or neck, it is essential to consult with a healthcare professional for an accurate diagnosis and appropriate treatment.

There are several different types of leukemia, including:

1. Acute Lymphoblastic Leukemia (ALL): This is the most common type of leukemia in children, but it can also occur in adults. It is characterized by an overproduction of immature white blood cells called lymphoblasts.
2. Acute Myeloid Leukemia (AML): This type of leukemia affects the bone marrow's ability to produce red blood cells, platelets, and other white blood cells. It can occur at any age but is most common in adults.
3. Chronic Lymphocytic Leukemia (CLL): This type of leukemia affects older adults and is characterized by the slow growth of abnormal white blood cells called lymphocytes.
4. Chronic Myeloid Leukemia (CML): This type of leukemia is caused by a genetic mutation in a gene called BCR-ABL. It can occur at any age but is most common in adults.
5. Hairy Cell Leukemia: This is a rare type of leukemia that affects older adults and is characterized by the presence of abnormal white blood cells called hairy cells.
6. Myelodysplastic Syndrome (MDS): This is a group of disorders that occur when the bone marrow is unable to produce healthy blood cells. It can lead to leukemia if left untreated.

Treatment for leukemia depends on the type and severity of the disease, but may include chemotherapy, radiation therapy, targeted therapy, or stem cell transplantation.

Types of experimental neoplasms include:

* Xenografts: tumors that are transplanted into animals from another species, often humans.
* Transgenic tumors: tumors that are created by introducing cancer-causing genes into an animal's genome.
* Chemically-induced tumors: tumors that are caused by exposure to certain chemicals or drugs.

The use of experimental neoplasms in research has led to significant advances in our understanding of cancer biology and the development of new treatments for the disease. However, the use of animals in cancer research is a controversial topic and alternatives to animal models are being developed and implemented.

Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.

The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:

1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.

The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:

1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.

The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:

1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.

It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.

Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.

Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.

Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.

The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.




Myeloid leukemia can be classified into several subtypes based on the type of cell involved and the degree of maturity of the abnormal cells. The most common types of myeloid leukemia include:

1. Acute Myeloid Leukemia (AML): This is the most aggressive form of myeloid leukemia, characterized by a rapid progression of immature cells that do not mature or differentiate into normal cells. AML can be further divided into several subtypes based on the presence of certain genetic mutations or chromosomal abnormalities.
2. Chronic Myeloid Leukemia (CML): This is a slower-growing form of myeloid leukemia, characterized by the presence of a genetic abnormality known as the Philadelphia chromosome. CML is typically treated with targeted therapies or bone marrow transplantation.
3. Myelodysplastic Syndrome (MDS): This is a group of disorders characterized by the impaired development of immature blood cells in the bone marrow. MDS can progress to AML if left untreated.
4. Chronic Myelomonocytic Leukemia (CMML): This is a rare form of myeloid leukemia that is characterized by the accumulation of immature monocytes in the blood and bone marrow. CMML can be treated with chemotherapy or bone marrow transplantation.

The symptoms of myeloid leukemia can vary depending on the subtype and severity of the disease. Common symptoms include fatigue, weakness, fever, night sweats, and weight loss. Diagnosis is typically made through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment options for myeloid leukemia can include chemotherapy, targeted therapies, bone marrow transplantation, and supportive care to manage symptoms and prevent complications. The prognosis for myeloid leukemia varies depending on the subtype of the disease and the patient's overall health. With current treatments, many patients with myeloid leukemia can achieve long-term remission or even be cured.

Sarcomas can arise in any part of the body, but they are most common in the arms and legs. They can also occur in the abdomen, chest, or head and neck. There are many different types of sarcoma, each with its own unique characteristics and treatment options.

The causes of sarcoma are not fully understood, but genetic mutations, exposure to radiation, and certain chemicals have been linked to an increased risk of developing the disease. Sarcomas can be challenging to diagnose and treat, as they often grow slowly and may not cause symptoms until they are advanced.

Treatment for sarcoma typically involves a combination of surgery, radiation therapy, and chemotherapy. The specific treatment plan will depend on the type of sarcoma, its location, and the stage of the disease. In some cases, amputation may be necessary to remove the tumor.

Prognosis for sarcoma varies depending on the type of cancer, the size and location of the tumor, and the stage of the disease. In general, the prognosis is best for patients with early-stage sarcoma that is confined to a small area and has not spread to other parts of the body.

Overall, sarcoma is a rare and complex form of cancer that requires specialized treatment and care. While the prognosis can vary depending on the specific type of cancer and the stage of the disease, advances in medical technology and treatment options have improved outcomes for many patients with sarcoma.

There are several types of drug-related side effects and adverse reactions, including:

1. Common side effects: These are side effects that are commonly experienced by patients taking a particular medication. Examples include nausea, dizziness, and fatigue.
2. Serious side effects: These are side effects that can be severe or life-threatening. Examples include allergic reactions, liver damage, and bone marrow suppression.
3. Adverse events: These are any unwanted or harmful effects that occur during the use of a medication, including side effects and other clinical events such as infections or injuries.
4. Drug interactions: These are interactions between two or more drugs that can cause harmful side effects or reduce the effectiveness of one or both drugs.
5. Side effects caused by drug abuse: These are side effects that occur when a medication is taken in larger-than-recommended doses or in a manner other than as directed. Examples include hallucinations, seizures, and overdose.

It's important to note that not all side effects and adverse reactions are caused by the drug itself. Some may be due to other factors, such as underlying medical conditions, other medications being taken, or environmental factors.

To identify and manage drug-related side effects and adverse reactions, healthcare providers will typically ask patients about any symptoms they are experiencing, perform physical exams, and review the patient's medical history and medication list. In some cases, additional tests may be ordered to help diagnose and manage the problem.

Overall, it's important for patients taking medications to be aware of the potential for side effects and adverse reactions, and to report any symptoms or concerns to their healthcare provider promptly. This can help ensure that any issues are identified and addressed early, minimizing the risk of harm and ensuring that the patient receives the best possible care.

There are several types of gliomas, including:

1. Astrocytoma: This is the most common type of glioma, accounting for about 50% of all cases. It arises from the star-shaped cells called astrocytes that provide support and nutrients to the brain's nerve cells.
2. Oligodendroglioma: This type of glioma originates from the oligodendrocytes, which are responsible for producing the fatty substance called myelin that insulates the nerve fibers.
3. Glioblastoma (GBM): This is the most aggressive and malignant type of glioma, accounting for about 70% of all cases. It is fast-growing and often spreads to other parts of the brain.
4. Brain stem glioma: This type of glioma arises in the brain stem, which is responsible for controlling many of the body's vital functions such as breathing, heart rate, and blood pressure.

The symptoms of glioma depend on the location and size of the tumor. Common symptoms include headaches, seizures, weakness or numbness in the arms or legs, and changes in personality, memory, or speech.

Gliomas are diagnosed through a combination of imaging tests such as CT or MRI scans, and tissue biopsy to confirm the presence of cancer cells. Treatment options for glioma depend on the type and location of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment to remove as much of the tumor as possible, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells.

The prognosis for glioma patients varies depending on the type and location of the tumor, as well as the patient's overall health. In general, the prognosis is better for patients with slow-growing, low-grade tumors, while those with fast-growing, high-grade tumors have a poorer prognosis. Overall, the 5-year survival rate for glioma patients is around 30-40%.

A residual neoplasm is a remaining portion of a tumor that may persist after primary treatment. This can occur when the treatment does not completely remove all of the cancer cells or if some cancer cells are resistant to the treatment. Residual neoplasms can be benign (non-cancerous) or malignant (cancerous).

It is important to note that a residual neoplasm does not necessarily mean that the cancer has come back. In some cases, a residual neoplasm may be present from the start and may not grow or change over time.

Residual neoplasms can be managed with additional treatment, such as surgery, chemotherapy, or radiation therapy. The choice of treatment depends on the type of cancer, the size and location of the residual neoplasm, and other factors.

It is important to follow up with your healthcare provider regularly to monitor the residual neoplasm and ensure that it is not growing or causing any symptoms.

Malignant prostatic neoplasms are cancerous tumors that can be aggressive and spread to other parts of the body (metastasize). The most common type of malignant prostatic neoplasm is adenocarcinoma of the prostate, which accounts for approximately 95% of all prostate cancers. Other types of malignant prostatic neoplasms include sarcomas and small cell carcinomas.

Prostatic neoplasms can be diagnosed through a variety of tests such as digital rectal examination (DRE), prostate-specific antigen (PSA) test, imaging studies (ultrasound, CT scan or MRI), and biopsy. Treatment options for prostatic neoplasms depend on the type, stage, and grade of the tumor, as well as the patient's age and overall health. Treatment options can include active surveillance, surgery (robotic-assisted laparoscopic prostatectomy or open prostatectomy), radiation therapy (external beam radiation therapy or brachytherapy), and hormone therapy.

In summary, Prostatic Neoplasms are tumors that occur in the prostate gland, which can be benign or malignant. The most common types of malignant prostatic neoplasms are adenocarcinoma of the prostate, and other types include sarcomas and small cell carcinomas. Diagnosis is done through a variety of tests, and treatment options depend on the type, stage, and grade of the tumor, as well as the patient's age and overall health.

DLBCL is characterized by the rapid growth of malignant B cells in the lymph nodes, spleen, bone marrow, and other organs. These cells can also spread to other parts of the body through the bloodstream or lymphatic system. The disease is often aggressive and can progress quickly without treatment.

The symptoms of DLBCL vary depending on the location and extent of the disease, but they may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Night sweats
* Weight loss
* Abdominal pain or discomfort
* Itching

The diagnosis of DLBCL is based on a combination of physical examination findings, imaging studies (such as CT scans or PET scans), and biopsy results. Treatment typically involves a combination of chemotherapy, radiation therapy, and in some cases, immunotherapy or targeted therapy. The prognosis for DLBCL has improved significantly over the past few decades, with overall survival rates ranging from 60% to 80%, depending on the stage and other factors.

Retroperitoneal neoplasms can occur in various locations, including the kidney, adrenal gland, pancreas, liver, spleen, and small intestine. These tumors can cause a variety of symptoms, such as abdominal pain, weight loss, fever, and difficulty urinating or passing stool.

The diagnosis of retroperitoneal neoplasms is based on a combination of imaging studies, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, and a biopsy, which involves removing a small sample of tissue from the suspected tumor and examining it under a microscope.

Treatment options for retroperitoneal neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment, and may involve removing the tumor and any affected surrounding tissue or organs. Radiation therapy and chemotherapy may also be used to shrink the tumor before surgery or to kill any remaining cancer cells after surgery.

Some common types of retroperitoneal neoplasms include:

1. Renal cell carcinoma (RCC): a type of kidney cancer that originates in the cells that line the renal tubules.
2. Adrenocortical carcinoma: a type of cancer that arises in the adrenal gland.
3. Pancreatic neuroendocrine tumors: tumors that arise in the pancreas and produce excess hormones.
4. Liver cancer (hepatocellular carcinoma): a type of cancer that originates in the liver cells.
5. Gastrointestinal stromal tumors (GISTs): tumors that arise in the digestive system, usually in the stomach or small intestine.
6. Soft tissue sarcomas: tumors that arise in the soft tissues of the body, such as the muscles, fat, and connective tissue.
7. Retroperitoneal fibrosis: a condition where the tissue in the retroperitoneum becomes scarred and thickened.
8. Metastatic tumors: tumors that have spread to the retroperitoneum from another part of the body, such as the lung, breast, or colon.

It is important to note that this is not an exhaustive list and there may be other types of retroperitoneal neoplasms not mentioned here. If you suspect you may have a retroperitoneal neoplasm, it is important to consult with a qualified medical professional for proper diagnosis and treatment.

There are several types of melanoma, including:

1. Superficial spreading melanoma: This is the most common type of melanoma, accounting for about 70% of cases. It usually appears as a flat or slightly raised discolored patch on the skin.
2. Nodular melanoma: This type of melanoma is more aggressive and accounts for about 15% of cases. It typically appears as a raised bump on the skin, often with a darker color.
3. Acral lentiginous melanoma: This type of melanoma affects the palms of the hands, soles of the feet, or nail beds and accounts for about 5% of cases.
4. Lentigo maligna melanoma: This type of melanoma usually affects the face and is more common in older adults.

The risk factors for developing melanoma include:

1. Ultraviolet (UV) radiation exposure from the sun or tanning beds
2. Fair skin, light hair, and light eyes
3. A history of sunburns
4. Weakened immune system
5. Family history of melanoma

The symptoms of melanoma can vary depending on the type and location of the cancer. Common symptoms include:

1. Changes in the size, shape, or color of a mole
2. A new mole or growth on the skin
3. A spot or sore that bleeds or crusts over
4. Itching or pain on the skin
5. Redness or swelling around a mole

If melanoma is suspected, a biopsy will be performed to confirm the diagnosis. Treatment options for melanoma depend on the stage and location of the cancer and may include surgery, chemotherapy, radiation therapy, or a combination of these. Early detection and treatment are key to successful outcomes in melanoma cases.

In conclusion, melanoma is a type of skin cancer that can be deadly if not detected early. It is important to practice sun safety, perform regular self-exams, and seek medical attention if any suspicious changes are noticed on the skin. By being aware of the risk factors, symptoms, and treatment options for melanoma, individuals can take steps to protect themselves from this potentially deadly disease.

Seminoma is a rare tumor that develops in the male reproductive organs, specifically in the seminiferous tubules of the testis. It is the most common type of germ cell tumor (GCT) and typically affects men between 20-40 years old. Seminomas are relatively slow-growing and have a good prognosis if detected early, with a high survival rate. Treatment for seminoma usually involves the removal of the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence.

Seminoma is a rare type of cancer that develops in the testicles of males, specifically in the seminiferous tubules. It is the most common form of germ cell tumor (GCT) and usually affects young men between 20-40 years old. Seminomas are slow-growing and have a good prognosis if detected early, with a high survival rate. Treatment for seminoma involves surgery to remove the affected testicle (orchiectomy), followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare type of cancer that affects men in their reproductive years, typically between 20-40. It originates from the cells responsible for producing sperm within the testicles and accounts for about one-third of all testicular cancers. Seminomas are usually slow-growing and have a relatively high survival rate if detected early. Treatment typically involves surgery to remove the affected testicle, followed by radiation therapy or chemotherapy to prevent recurrence.

Seminoma is a rare form of cancer that develops in the testicles of males, making up about one-third of all testicular cancers. It originates from the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. Seminomas are slow-growing and have a good prognosis if detected early, with a high survival rate. Treatment involves surgery to remove the affected testicle (orchiectomy), followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is an uncommon form of cancer that develops in the testicles of males, making up about one-third of all testicular cancers. It originates from the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. Seminomas are slow-growing and have a relatively high survival rate if detected early, with a five-year survival rate of about 95%. Treatment usually involves surgery to remove the affected testicle (orchiectomy), followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare form of testicular cancer that accounts for approximately one-third of all cases. It develops from the cells responsible for producing sperm within the seminiferous tubules and most commonly affects men between 20-40 years old. Seminomas are slow-growing and have a good prognosis if detected early, with a five-year survival rate of about 95%. Treatment typically involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is an uncommon form of cancer that develops in the testicles of males, accounting for approximately one-third of all testicular cancers. It originates from the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. Seminomas are slow-growing and have a high survival rate if detected early, with a five-year survival rate of about 95%. Treatment usually involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare and slow-growing form of testicular cancer that accounts for approximately one-third of all cases. It develops from the cells responsible for producing sperm within the seminiferous tubules and most commonly affects men between 20-40 years old. Seminomas have a good prognosis if detected early, with a five-year survival rate of about 95%. Treatment typically involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is an uncommon type of testicular cancer that accounts for approximately one-third of all cases. It develops in the cells responsible for producing sperm within the seminiferous tubules and most commonly affects men between 20-40 years old. Seminomas are slow-growing and have a high survival rate if detected early, with a five-year survival rate of about 95%. Treatment typically involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare and slow-growing type of testicular cancer that accounts for about one-third of all cases. It develops in the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. If detected early, seminomas have a good prognosis with a five-year survival rate of about 95%. Treatment usually involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is an uncommon type of testicular cancer that accounts for approximately one-third of all cases. It develops in the cells responsible for producing sperm within the seminiferous tubules and most commonly affects men between 20-40 years old. Seminomas are slow-growing and have a high survival rate if detected early, with a five-year survival rate of about 95%. Treatment typically involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare form of testicular cancer that accounts for approximately one-third of all cases. It develops in the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. Seminomas are slow-growing and have a good prognosis, with a five-year survival rate of about 95% if detected early. Treatment usually involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare and slow-growing type of testicular cancer that accounts for approximately one-third of all cases. It develops in the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. Seminomas have a high survival rate if detected early, with a five-year survival rate of about 95%. Treatment usually involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare form of testicular cancer that accounts for approximately one-third of all cases. It develops in the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. Seminomas are slow-growing and have a good prognosis, with a five-year survival rate of about 95% if detected early. Treatment usually involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Seminoma is a rare and slow-growing type of testicular cancer that accounts for approximately one-third of all cases. It develops in the cells responsible for producing sperm within the seminiferous tubules and typically affects men between 20-40 years old. Seminomas have a high survival rate if detected early, with a five-year survival rate of about 95%. Treatment usually involves surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Testicular cancer is rare and typically affects men between 20-40 years old. There are two main types: seminoma and non-seminoma. Seminoma is a slow-growing form that accounts for approximately one-third of all cases and has a good prognosis with early detection and treatment. Non-seminoma is more aggressive and makes up about 70% of cases, with a five-year survival rate of about 95% if detected early. Treatment options include surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.

Testicular cancer is relatively rare and typically affects men between 20-40 years old. There are two main types: seminoma and non-seminoma, with seminoma being slow-growing and accounting for approximately one-third of all cases. Non-seminoma is more aggressive, making up about 70% of cases, and has a five-year survival rate of about 95% if detected early. Treatment options include surgery to remove the affected testicle (orchiectomy) followed by radiation therapy or chemotherapy to prevent recurrence of the cancer.




Mediastinal neoplasms are tumors or abnormal growths that occur in the mediastinum, which is the area between the lungs in the chest cavity. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Types of Mediastinal Neoplasms
------------------------------

There are several types of mediastinal neoplasms, including:

1. Thymoma: A tumor that originates in the thymus gland.
2. Thymic carcinoma: A malignant tumor that originates in the thymus gland.
3. Lymphoma: Cancer of the immune system that can occur in the mediastinum.
4. Germ cell tumors: Tumors that originate from germ cells, which are cells that form eggs or sperm.
5. Neuroendocrine tumors: Tumors that originate from cells of the nervous system and produce hormones.
6. Mesothelioma: A type of cancer that occurs in the lining of the chest cavity.
7. Metastatic tumors: Tumors that have spread to the mediastinum from another part of the body, such as the breast, lung, or colon.

Symptoms of Mediastinal Neoplasms
------------------------------

The symptoms of mediastinal neoplasms can vary depending on the type and location of the tumor. Some common symptoms include:

1. Chest pain or discomfort
2. Shortness of breath
3. Coughing
4. Fatigue
5. Weight loss
6. Swelling in the neck or face
7. Pain in the shoulders or arms
8. Coughing up blood
9. Hoarseness or difficulty swallowing

Diagnosis and Treatment of Mediastinal Neoplasms
-----------------------------------------------

The diagnosis of mediastinal neoplasms typically involves a combination of imaging tests such as chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. A biopsy may also be performed to confirm the diagnosis.

Treatment for mediastinal neoplasms depends on the type and location of the tumor, as well as the patient's overall health. Treatment options can include:

1. Surgery: Surgical removal of the tumor may be possible for some types of mediastinal neoplasms.
2. Radiation therapy: High-energy beams can be used to kill cancer cells.
3. Chemotherapy: Drugs can be used to kill cancer cells.
4. Targeted therapy: Drugs that target specific molecules involved in the growth and spread of cancer cells.
5. Immunotherapy: A type of treatment that uses the body's immune system to fight cancer.

Prognosis for Mediastinal Neoplasms
---------------------------------

The prognosis for mediastinal neoplasms depends on the type and location of the tumor, as well as the patient's overall health. In general, the prognosis is good for benign tumors, while the prognosis is guarded for malignant tumors. Factors that can affect the prognosis include:

1. Tumor size and location
2. Type of tumor
3. Extent of cancer spread
4. Patient's age and overall health
5. Response to treatment

Lifestyle Changes for Patients with Mediastinal Neoplasms
---------------------------------------------------

Patients with mediastinal neoplasms may need to make lifestyle changes to help manage their symptoms and improve their quality of life. These can include:

1. Eating a healthy diet
2. Getting regular exercise
3. Avoiding smoking and alcohol
4. Managing stress
5. Getting enough rest and sleep
6. Attending follow-up appointments with the doctor

Conclusion
----------

Mediastinal neoplasms are tumors that occur in the mediastinum, a region of the chest between the lungs. They can be benign or malignant, and their symptoms and treatment options vary depending on the type and location of the tumor. If you have been diagnosed with a mediastinal neoplasm, it is important to work closely with your healthcare team to determine the best course of treatment and manage any symptoms you may be experiencing. With appropriate treatment and lifestyle changes, many patients with mediastinal neoplasms can achieve long-term survival and a good quality of life.

It is also known as mouth inflammation.

The term "Sarcoma 180" was coined by a German surgeon named Otto Kunkel in the early 20th century. He described this type of cancer as a highly malignant tumor that grows slowly but is resistant to treatment with surgery, radiation therapy, and chemotherapy.

The exact cause of Sarcoma 180 is not known, but it is believed to be linked to genetic mutations and exposure to certain chemicals or radiation. The disease typically affects middle-aged adults and is more common in men than women.

The symptoms of Sarcoma 180 can vary depending on the location of the tumor, but they may include pain, swelling, redness, and limited mobility in the affected area. If left untreated, the cancer can spread to other parts of the body and be fatal.

Treatment for Sarcoma 180 usually involves a combination of surgery, radiation therapy, and chemotherapy. In some cases, amputation of the affected limb may be necessary. The prognosis for this disease is generally poor, with a five-year survival rate of less than 50%.

In summary, Sarcoma 180 is a rare and aggressive form of cancer that affects connective tissue and has a poor prognosis. It is important for medical professionals to be aware of this condition and its symptoms in order to provide proper diagnosis and treatment.

Benign CNS neoplasms include:

1. Meningiomas: These are the most common type of benign CNS tumor, arising from the meninges (the membranes covering the brain and spinal cord).
2. Acoustic neuromas: These tumors arise from the nerve cells that connect the inner ear to the brain.
3. Pineal gland tumors: These are rare tumors that occur in the pineal gland, a small gland located in the brain.
4. Craniopharyngiomas: These are rare tumors that arise from the remnants of the embryonic pituitary gland and can cause a variety of symptoms including headaches, vision loss, and hormonal imbalances.

Malignant CNS neoplasms include:

1. Gliomas: These are the most common type of malignant CNS tumor and arise from the supporting cells of the brain called glial cells. Examples of gliomas include astrocytomas, oligodendrogliomas, and medulloblastomas.
2. Lymphomas: These are cancers of the immune system that can occur in the CNS.
3. Melanomas: These are rare tumors that arise from the pigment-producing cells of the skin and can spread to other parts of the body, including the CNS.
4. Metastatic tumors: These are tumors that have spread to the CNS from other parts of the body, such as the breast, lung, or colon.

The diagnosis and treatment of central nervous system neoplasms depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.

The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment. In general, gliomas have a poorer prognosis than other types of CNS tumors, with five-year survival rates ranging from 30% to 60%. Lymphomas and melanomas have better prognoses, with five-year survival rates of up to 80%. Metastatic tumors have a more guarded prognosis, with five-year survival rates depending on the primary site of the cancer.

In summary, central nervous system neoplasms are abnormal growths of tissue in the brain and spinal cord that can cause a variety of symptoms and can be benign or malignant. The diagnosis and treatment of these tumors depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment, but in general, gliomas have a poorer prognosis than other types of CNS tumors.

Previous articleNeoplastic Cells
Next articleNephrocalcinosis

Examples of hematologic diseases include:

1. Anemia - a condition where there are not enough red blood cells or hemoglobin in the body.
2. Leukemia - a type of cancer that affects the bone marrow and blood, causing an overproduction of immature white blood cells.
3. Lymphoma - a type of cancer that affects the lymphatic system, including the bone marrow, spleen, and lymph nodes.
4. Thalassemia - a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.
5. Sickle cell disease - a genetic disorder that affects the production of hemoglobin, causing red blood cells to become sickle-shaped and prone to breaking down.
6. Polycythemia vera - a rare disorder where there is an overproduction of red blood cells.
7. Myelodysplastic syndrome - a condition where the bone marrow produces abnormal blood cells that do not mature properly.
8. Myeloproliferative neoplasms - a group of conditions where the bone marrow produces excessive amounts of blood cells, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
9. Deep vein thrombosis - a condition where a blood clot forms in a deep vein, often in the leg or arm.
10. Pulmonary embolism - a condition where a blood clot travels to the lungs and blocks a blood vessel, causing shortness of breath, chest pain, and other symptoms.

These are just a few examples of hematologic diseases, but there are many others that can affect the blood and bone marrow. Treatment options for these diseases can range from watchful waiting and medication to surgery, chemotherapy, and stem cell transplantation. It is important to seek medical attention if you experience any symptoms of hematologic disease, as early diagnosis and treatment can improve outcomes.

Neuroblastoma is caused by a genetic mutation that affects the development and growth of nerve cells. The cancerous cells are often sensitive to chemotherapy, but they can be difficult to remove surgically because they are deeply embedded in the nervous system.

There are several different types of neuroblastoma, including:

1. Infantile neuroblastoma: This type of neuroblastoma occurs in children under the age of one and is often more aggressive than other types of the cancer.
2. Juvenile neuroblastoma: This type of neuroblastoma occurs in children between the ages of one and five and tends to be less aggressive than infantile neuroblastoma.
3. Adult neuroblastoma: This type of neuroblastoma occurs in adults and is rare.
4. Metastatic neuroblastoma: This type of neuroblastoma has spread to other parts of the body, such as the bones or liver.

Symptoms of neuroblastoma can vary depending on the location and size of the tumor, but they may include:

* Abdominal pain
* Fever
* Loss of appetite
* Weight loss
* Fatigue
* Bone pain
* Swelling in the abdomen or neck
* Constipation
* Increased heart rate

Diagnosis of neuroblastoma typically involves a combination of imaging tests, such as CT scans and MRI scans, and biopsies to confirm the presence of cancerous cells. Treatment for neuroblastoma usually involves a combination of chemotherapy, surgery, and radiation therapy. The prognosis for neuroblastoma varies depending on the type of cancer, the age of the child, and the stage of the disease. In general, the younger the child and the more aggressive the treatment, the better the prognosis.

Types of Esophageal Neoplasms:

1. Barrett's Esophagus: This is a precancerous condition that occurs when the cells lining the esophagus undergo abnormal changes, increasing the risk of developing esophageal cancer.
2. Adenocarcinoma: This is the most common type of esophageal cancer, accounting for approximately 70% of all cases. It originates in the glands that line the esophagus.
3. Squamous Cell Carcinoma: This type of cancer accounts for about 20% of all esophageal cancers and originates in the squamous cells that line the esophagus.
4. Other rare types: Other rare types of esophageal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Causes and Risk Factors:

1. Gastroesophageal reflux disease (GERD): Long-standing GERD can lead to the development of Barrett's esophagus, which is a precancerous condition that increases the risk of developing esophageal cancer.
2. Obesity: Excess body weight is associated with an increased risk of developing esophageal cancer.
3. Diet: A diet high in processed meats and low in fruits and vegetables may increase the risk of developing esophageal cancer.
4. Alcohol consumption: Heavy alcohol consumption is a known risk factor for esophageal cancer.
5. Smoking: Cigarette smoking is a major risk factor for esophageal cancer.
6. Family history: Having a family history of esophageal cancer or other cancers may increase an individual's risk.
7. Age: The risk of developing esophageal cancer increases with age, with most cases occurring in people over the age of 50.
8. Other medical conditions: Certain medical conditions, such as achalasia, may increase the risk of developing esophageal cancer.

Symptoms and Diagnosis:

1. Dysphagia (difficulty swallowing): This is the most common symptom of esophageal cancer, and can be caused by a narrowing or blockage of the esophagus due to the tumor.
2. Chest pain or discomfort: Pain in the chest or upper back can be a symptom of esophageal cancer.
3. Weight loss: Losing weight without trying can be a symptom of esophageal cancer.
4. Coughing or hoarseness: If the tumor is obstructing the airway, it can cause coughing or hoarseness.
5. Fatigue: Feeling tired or weak can be a symptom of esophageal cancer.
6. Diagnosis: A diagnosis of esophageal cancer is typically made through a combination of endoscopy, imaging tests (such as CT scans), and biopsies.

Treatment Options:

1. Surgery: Surgery is the primary treatment for esophageal cancer, and can involve removing the tumor and some surrounding tissue, or removing the entire esophagus and replacing it with a section of stomach or intestine.
2. Chemotherapy: Chemotherapy involves using drugs to kill cancer cells, and is often used in combination with surgery to treat esophageal cancer.
3. Radiation therapy: Radiation therapy uses high-energy X-rays to kill cancer cells, and can be used alone or in combination with surgery or chemotherapy.
4. Targeted therapy: Targeted therapy drugs are designed to target specific molecules that are involved in the growth and spread of cancer cells, and can be used in combination with other treatments.

Prognosis and Survival Rate:

1. The prognosis for esophageal cancer is generally poor, with a five-year survival rate of around 20%.
2. Factors that can improve the prognosis include early detection, small tumor size, and absence of spread to lymph nodes or other organs.
3. The overall survival rate for esophageal cancer has not improved much over the past few decades, but advances in treatment have led to a slight increase in survival time for some patients.

Lifestyle Changes and Prevention:

1. Avoiding tobacco and alcohol: Tobacco and alcohol are major risk factors for esophageal cancer, so avoiding them can help reduce the risk of developing the disease.
2. Maintaining a healthy diet: Eating a balanced diet that is high in fruits, vegetables, and whole grains can help protect against esophageal cancer.
3. Managing obesity: Obesity is a risk factor for esophageal cancer, so maintaining a healthy weight through diet and exercise can help reduce the risk of developing the disease.
4. Reducing exposure to pollutants: Exposure to certain chemicals and pollutants, such as pesticides and asbestos, has been linked to an increased risk of esophageal cancer. Avoiding these substances can help reduce the risk of developing the disease.
5. Getting regular screening: Regular screening for Barrett's esophagus, a precancerous condition that can develop in people with gastroesophageal reflux disease (GERD), can help detect and treat esophageal cancer early, when it is most treatable.

Current Research and Future Directions:

1. Targeted therapies: Researchers are working on developing targeted therapies that can specifically target the genetic mutations that drive the growth of esophageal cancer cells. These therapies may be more effective and have fewer side effects than traditional chemotherapy.
2. Immunotherapy: Immunotherapy, which uses the body's immune system to fight cancer, is being studied as a potential treatment for esophageal cancer. Researchers are working on developing vaccines and other immunotherapies that can help the body recognize and attack cancer cells.
3. Precision medicine: With the help of advanced genomics and precision medicine, researchers are working to identify specific genetic mutations that drive the growth of esophageal cancer in each patient. This information can be used to develop personalized treatment plans that are tailored to the individual patient's needs.
4. Early detection: Researchers are working on developing new methods for early detection of esophageal cancer, such as using machine learning algorithms to analyze medical images and detect signs of cancer at an early stage.
5. Lifestyle modifications: Studies have shown that lifestyle modifications, such as quitting smoking and maintaining a healthy diet, can help reduce the risk of developing esophageal cancer. Researchers are working on understanding the specific mechanisms by which these modifications can help prevent the disease.

In conclusion, esophageal cancer is a complex and aggressive disease that is often diagnosed at an advanced stage. However, with advances in technology, research, and treatment options, there is hope for improving outcomes for patients with this disease. By understanding the risk factors, early detection methods, and current treatments, as well as ongoing research and future directions, we can work towards a future where esophageal cancer is more manageable and less deadly.

Rectal neoplasms refer to abnormal growths or tumors that occur in the rectum, which is the lower part of the digestive system. These growths can be benign (non-cancerous) or malignant (cancerous).

Types of Rectal Neoplasms:

There are several types of rectal neoplasms, including:

1. Adenoma: A benign growth that is usually found in the colon and rectum. It is a common precursor to colorectal cancer.
2. Carcinoma: A malignant tumor that arises from the epithelial cells lining the rectum. It is the most common type of rectal cancer.
3. Rectal adenocarcinoma: A type of carcinoma that originates in the glandular cells lining the rectum.
4. Rectal squamous cell carcinoma: A type of carcinoma that originates in the squamous cells lining the rectum.
5. Rectal melanoma: A rare type of carcinoma that originates in the pigment-producing cells (melanocytes) of the rectum.

Causes and Risk Factors:

The exact causes of rectal neoplasms are not known, but several factors can increase the risk of developing these growths. These include:

1. Age: The risk of developing rectal neoplasms increases with age, with most cases occurring in people over the age of 50.
2. Family history: Having a family history of colorectal cancer or polyps can increase the risk of developing rectal neoplasms.
3. Inflammatory bowel disease: People with inflammatory bowel disease, such as ulcerative colitis and Crohn's disease, are at higher risk of developing rectal neoplasms.
4. Diet: A diet high in fat and low in fiber may increase the risk of developing rectal neoplasms.
5. Lifestyle factors: Factors such as smoking, obesity, and lack of physical activity may also increase the risk of developing rectal neoplasms.

Symptoms:

The symptoms of rectal neoplasms can vary depending on the type and location of the growth. Some common symptoms include:

1. Blood in the stool
2. Changes in bowel movements (such as diarrhea or constipation)
3. Abdominal pain or discomfort
4. Weakness and fatigue
5. Loss of appetite

Diagnosis:

To diagnose rectal neoplasms, a doctor may perform several tests, including:

1. Digital rectal exam (DRE): A doctor will insert a gloved finger into the rectum to feel for any abnormalities.
2. Colonoscopy: A flexible tube with a camera and light on the end is inserted through the anus and into the rectum to examine the inside of the rectum and colon for polyps or other abnormalities.
3. Imaging tests: Such as X-rays, CT scans, or MRI scans to visualize the growth and determine its location and size.
4. Biopsy: A sample of tissue is removed from the rectum and examined under a microscope for cancer cells.

Treatment:

The treatment of rectal neoplasms depends on the type, location, and stage of the growth. Some common treatments include:

1. Polypectomy: Removal of polyps through a colonoscopy or surgery.
2. Local excision: Surgical removal of the tumor and a small amount of surrounding tissue.
3. Radiation therapy: High-energy beams are used to kill cancer cells.
4. Chemotherapy: Drugs are used to kill cancer cells.
5. Immunotherapy: A treatment that uses the body's immune system to fight cancer.

Prognosis:

The prognosis for rectal neoplasms depends on the type, location, and stage of the growth. In general, the earlier the diagnosis and treatment, the better the prognosis. However, some types of rectal neoplasms can be more aggressive and difficult to treat, and may have a poorer prognosis.

Prevention:

There is no sure way to prevent rectal neoplasms, but there are several screening tests that can help detect them early, including:

1. Colonoscopy: A test in which a flexible tube with a camera and light on the end is inserted into the rectum and colon to examine for polyps or cancer.
2. Fecal occult blood test (FOBT): A test that checks for blood in the stool.
3. Flexible sigmoidoscopy: A test similar to a colonoscopy, but only examines the lower part of the colon and rectum.
4. Digital rectal exam (DRE): An examination of the rectum using a gloved finger to feel for any abnormalities.

It is important to talk to your doctor about your risk for rectal neoplasms and any screening tests that may be appropriate for you. Early detection and treatment can improve the prognosis for these types of growths.

Symptoms of dysgerminoma may include abdominal pain, pelvic pain, bloating, and irregular vaginal bleeding. The tumor can also cause elevated levels of certain proteins, such as CA125, in the blood.

Dysgerminoma is diagnosed through a combination of imaging tests, such as ultrasound and CT scans, and a biopsy to confirm the presence of cancer cells. Treatment typically involves a combination of surgery and chemotherapy, with the goal of removing all visible tumor deposits and reducing the risk of recurrence.

Prognosis for dysgerminoma varies depending on the stage and aggressiveness of the tumor. Early detection and treatment can improve survival rates, but this type of cancer is generally more difficult to treat than other types of ovarian cancer.

Overall, dysgerminoma is a rare and aggressive form of ovarian cancer that requires specialized care and attention from medical professionals. With advances in diagnosis and treatment, women with this condition have a better chance of successful management and a positive outcome.

Most nasopharyngeal neoplasms are rare and tend to affect children and young adults more frequently than older adults. The most common types of nasopharyngeal neoplasms include:

1. Nasopharyngeal carcinoma (NPC): This is the most common type of malignant nasopharyngeal neoplasm and tends to affect young adults in Southeast Asia more frequently than other populations.
2. Adenoid cystic carcinoma: This is a rare, slow-growing tumor that usually affects the nasopharynx and salivary glands.
3. Metastatic squamous cell carcinoma: This is a type of cancer that originates in another part of the body (usually the head and neck) and spreads to the nasopharynx.
4. Lymphoma: This is a type of cancer that affects the immune system and can occur in the nasopharynx.
5. Benign tumors: These include benign growths such as papillomas, fibromas, and meningiomas.

Symptoms of nasopharyngeal neoplasms can vary depending on the size and location of the tumor but may include:

* Difficulty swallowing
* Nosebleeds
* Headaches
* Facial pain or numbness
* Trouble breathing through the nose
* Hoarseness or voice changes
* Enlarged lymph nodes in the neck

Diagnosis of nasopharyngeal neoplasms usually involves a combination of imaging tests such as CT or MRI scans, endoscopy (insertion of a flexible tube with a camera into the nose and throat), and biopsy (removal of a small sample of tissue for examination under a microscope).

Treatment of nasopharyngeal neoplasms depends on the type, size, location, and stage of the tumor but may include:

* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules on cancer cells

Prognosis for nasopharyngeal neoplasms varies depending on the type and stage of the tumor but in general, early detection and treatment improve the chances of a successful outcome.

Examples of neoplasms, glandular and epithelial include:

* Adenomas: These are benign tumors that arise from glandular tissue. Examples include colon adenomas and prostate adenomas.
* Carcinomas: These are malignant tumors that arise from glandular or epithelial tissue. Examples include breast carcinoma, lung carcinoma, and ovarian carcinoma.
* Sarcomas: These are malignant tumors that arise from connective tissue. Examples include soft tissue sarcoma and bone sarcoma.

The diagnosis of neoplasms, glandular and epithelial is typically made through a combination of imaging tests such as X-rays, CT scans, MRI scans, and PET scans, along with a biopsy to confirm the presence of cancer cells. Treatment options for these types of neoplasms depend on the location, size, and stage of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Overall, the term "neoplasms, glandular and epithelial" refers to a wide range of tumors that arise from glandular or epithelial tissue, and can be either benign or malignant. These types of neoplasms are common and can affect many different parts of the body.

The symptoms of mesothelioma can vary depending on the location of the cancer, but they may include:

* Shortness of breath or pain in the chest (for pleural mesothelioma)
* Abdominal pain or swelling (for peritoneal mesothelioma)
* Fatigue or fever (for pericardial mesothelioma)
* Weight loss and night sweats

There is no cure for mesothelioma, but treatment options may include surgery, chemotherapy, and radiation therapy. The prognosis for mesothelioma is generally poor, with a five-year survival rate of about 5% to 10%. However, the outlook can vary depending on the type of mesothelioma, the stage of the cancer, and the patient's overall health.

Asbestos exposure is the primary risk factor for developing mesothelioma, and it is important to avoid exposure to asbestos in any form. This can be done by avoiding old buildings and products that contain asbestos, wearing protective clothing and equipment when working with asbestos, and following proper safety protocols when handling asbestos-containing materials.

In summary, mesothelioma is a rare and aggressive form of cancer that develops in the lining of the heart or abdomen due to exposure to asbestos. It can be difficult to diagnose and treat, and the prognosis is generally poor. However, with proper medical care and avoidance of asbestos exposure, patients with mesothelioma may have a better chance of survival.

Examples of soft tissue neoplasms include:

1. Lipoma: a benign tumor composed of fat cells.
2. Fibroma: a benign tumor composed of fibrous tissue.
3. Leiomyoma: a benign tumor composed of smooth muscle tissue.
4. Synovial sarcoma: a malignant tumor that arises in the soft tissues surrounding joints.
5. Rhabdomyosarcoma: a malignant tumor that arises in the skeletal muscles.
6. Neurofibroma: a benign tumor that arises in the nerve tissue.

Soft tissue neoplasms can occur in various parts of the body, including the extremities (arms and legs), trunk, and head and neck. They can be diagnosed through a combination of imaging studies such as X-rays, CT scans, MRI scans, and biopsy.

Treatment for soft tissue neoplasms depends on the type, size, location, and aggressiveness of the tumor, as well as the patient's overall health. Benign tumors may not require treatment, while malignant tumors may be treated with surgery, radiation therapy, or chemotherapy.

These tumors can be benign or malignant, and their growth and behavior vary depending on the type of cancer. Malignant tumors can invade the surrounding tissues and spread to other parts of the body through the bloodstream or lymphatic system, causing serious complications and potentially life-threatening consequences.

The risk factors for developing urinary bladder neoplasms include smoking, exposure to certain chemicals, recurrent bladder infections, and a family history of bladder cancer. The symptoms of these tumors can include blood in the urine, pain during urination, frequent urination, and abdominal pain.

Diagnosis of urinary bladder neoplasms is typically made through a combination of imaging tests such as ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI), and cystoscopy, which involves inserting a flexible tube with a camera into the bladder to visualize the tumor.

Treatment options for urinary bladder neoplasms depend on the type of cancer, stage, and location of the tumor. Treatment may include surgery to remove the tumor, chemotherapy, radiation therapy, or a combination of these modalities. Early detection and treatment can improve the prognosis for patients with urinary bladder neoplasms.

The signs and symptoms of CE can vary depending on the location of the tumor, but they may include:

* Lumps or swelling in the neck, underarm, or groin area
* Fever
* Fatigue
* Weight loss
* Night sweats
* Swollen lymph nodes
* Pain in the affected area

CE is caused by a genetic mutation that leads to uncontrolled cell growth and division. The exact cause of the mutation is not fully understood, but it is believed to be linked to exposure to certain viruses or chemicals.

Diagnosis of CE typically involves a combination of physical examination, imaging tests such as CT scans or PET scans, and biopsy to confirm the presence of cancer cells. Treatment options for CE depend on the stage and location of the tumor, but may include:

* Chemotherapy to kill cancer cells
* Radiation therapy to shrink the tumor
* Surgery to remove the tumor
* Immunotherapy to boost the immune system's ability to fight the cancer

Overall, CE is a rare and aggressive form of cancer that requires prompt diagnosis and treatment to improve outcomes.

Pathologic neovascularization can be seen in a variety of conditions, including cancer, diabetic retinopathy, and age-related macular degeneration. In cancer, for example, the formation of new blood vessels can help the tumor grow and spread to other parts of the body. In diabetic retinopathy, the growth of new blood vessels in the retina can cause vision loss and other complications.

There are several different types of pathologic neovascularization, including:

* Angiosarcoma: a type of cancer that arises from the cells lining blood vessels
* Hemangiomas: benign tumors that are composed of blood vessels
* Cavernous malformations: abnormal collections of blood vessels in the brain or other parts of the body
* Pyogenic granulomas: inflammatory lesions that can form in response to trauma or infection.

The diagnosis of pathologic neovascularization is typically made through a combination of physical examination, imaging studies (such as ultrasound, CT scans, or MRI), and biopsy. Treatment options vary depending on the underlying cause of the condition, but may include medications, surgery, or radiation therapy.

In summary, pathologic neovascularization is a process that occurs in response to injury or disease, and it can lead to serious complications. It is important for healthcare professionals to be aware of this condition and its various forms in order to provide appropriate diagnosis and treatment.

The term "mucositis" is derived from the Latin words "mucosa," meaning "membrane," and "-itis," meaning "inflammation." It is a relatively recently coined term that was first used in the medical literature in the 1980s to describe this specific type of inflammation. Mucositis is a common complication of various medical conditions, such as cancer, HIV/AIDS, and inflammatory bowel disease, and it can significantly impact quality of life and treatment outcomes. As a result, mucositis has become an area of increasing research focus in the fields of gastroenterology, oncology, and infectious diseases.

This definition is based on the current understanding of mucositis as a medical condition and may change as new research and clinical experience shed light on its causes, diagnosis, and treatment.

Sources:

1. National Institute of Diabetes and Digestive and Kidney Diseases. (2018). Mucositis. Retrieved from
2. American Cancer Society. (2020). Mouth and throat changes during cancer treatment. Retrieved from
3. Mayo Clinic. (2020). Mucositis. Retrieved from

The tumor develops from immature cells in the cerebellum called granule cells, and it can grow rapidly and spread to other parts of the brain. Medulloblastoma is usually diagnosed in the early stages, and treatment typically involves surgery, chemotherapy, and radiation therapy.

There are several subtypes of medulloblastoma, including:

* Winged-helix transcription factor (WHCT) medulloblastoma
* Sonic hedgehog (SHH) medulloblastoma
* Group 3 medulloblastoma
* Group 4 medulloblastoma

Each subtype has a different genetic profile and may require different treatment approaches.

Medulloblastoma is a rare cancer, but it is the most common type of pediatric brain cancer. With current treatments, the prognosis for medulloblastoma is generally good, especially for children who are diagnosed early and receive appropriate treatment. However, the cancer can recur in some cases, and ongoing research is focused on improving treatment outcomes and finding new, less toxic therapies for this disease.

In the medical field, fatigue is often evaluated using a combination of physical examination, medical history, and laboratory tests to determine its underlying cause. Treatment for fatigue depends on the underlying cause, but may include rest, exercise, stress management techniques, and medication.

Some common causes of fatigue in the medical field include:

1. Sleep disorders, such as insomnia or sleep apnea
2. Chronic illnesses, such as diabetes, heart disease, or arthritis
3. Infections, such as the flu or a urinary tract infection
4. Medication side effects
5. Poor nutrition or hydration
6. Substance abuse
7. Chronic stress
8. Depression or anxiety
9. Hormonal imbalances
10. Autoimmune disorders, such as thyroiditis or lupus.

Fatigue can also be a symptom of other medical conditions, such as:

1. Anemia
2. Hypoglycemia (low blood sugar)
3. Hypothyroidism (underactive thyroid)
4. Hyperthyroidism (overactive thyroid)
5. Chronic fatigue syndrome
6. Fibromyalgia
7. Vasculitis
8. Cancer
9. Heart failure
10. Liver or kidney disease.

It is important to seek medical attention if fatigue is severe, persistent, or accompanied by other symptoms such as fever, pain, or difficulty breathing. A healthcare professional can diagnose and treat the underlying cause of fatigue, improving overall quality of life.

Symptoms of Kidney Neoplasms can include blood in the urine, pain in the flank or abdomen, weight loss, fever, and fatigue. Diagnosis is made through a combination of physical examination, imaging studies such as CT scans or ultrasound, and tissue biopsy. Treatment options vary depending on the type and stage of the neoplasm, but may include surgery, ablation therapy, targeted therapy, or chemotherapy.

It is important for individuals with a history of Kidney Neoplasms to follow up with their healthcare provider regularly for monitoring and check-ups to ensure early detection of any recurrences or new tumors.

Benign pleural neoplasms include:

1. Pleomorphic adenoma: A rare, slow-growing tumor that usually occurs in the soft tissues of the chest wall.
2. Pneumoschisis: A condition where there is a tear or separation in the membrane that lines the lung, which can cause air to leak into the pleural space and create a benign tumor.
3. Pleural plaques: Calcified deposits that form in the pleura as a result of inflammation or injury.

Malignant pleural neoplasms include:

1. Mesothelioma: A rare and aggressive cancer that originates in the pleura, usually caused by exposure to asbestos.
2. Lung cancer: Cancer that spreads to the pleura from another part of the body, such as the lungs.
3. Metastatic tumors: Tumors that have spread to the pleura from another part of the body, such as the breast or colon.

Pleural neoplasms can cause a variety of symptoms, including chest pain, shortness of breath, coughing, and fatigue. Diagnosis is typically made through a combination of imaging tests, such as CT scans and PET scans, and a biopsy to confirm the presence of cancerous cells. Treatment options for pleural neoplasms depend on the type and stage of the tumor, and may include surgery, chemotherapy, and radiation therapy.

Examples of acute diseases include:

1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.

Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.

There are several types of retinal neoplasms, including:

1. Retinal angiomatosis: This is a benign tumor that grows new blood vessels in the retina.
2. Retinal astrocytoma: This is a malignant tumor that arises from the supportive cells of the retina called astrocytes.
3. Retinal melanoma: This is a malignant tumor that arises from the pigment-producing cells of the retina called melanocytes. It is the most common type of primary intraocular cancer (cancer that originates in the eye).
4. Retinal osteochondroma: This is a benign tumor that grows from the supporting tissue of the retina.
5. Retinal sarcoma: This is a malignant tumor that arises from the connective tissue of the retina.

Retinal neoplasms can cause a variety of symptoms, including:

1. Blurred vision
2. Distorted vision
3. Flashes of light
4. Floaters (specks or cobwebs in your vision)
5. Eye pain
6. Redness and swelling of the eye
7. Sensitivity to light
8. Difficulty seeing colors

If you experience any of these symptoms, it is important to see an eye doctor as soon as possible for a comprehensive examination. Retinal neoplasms can be diagnosed through a combination of physical examination, imaging tests such as ultrasound and MRI, and laboratory tests such as blood tests.

Treatment options for retinal neoplasms depend on the type and location of the tumor, as well as the severity of the symptoms. Some common treatment options include:

1. Observation: Small, benign tumors may not require immediate treatment and can be monitored with regular eye exams to see if they grow or change over time.
2. Photocoagulation: This is a procedure that uses laser light to damage the tumor and prevent it from growing further. It can be used to treat retinal melanoma and other types of retinal neoplasms.
3. Cryotherapy: This is a procedure that uses extreme cold to freeze and destroy the tumor. It can be used to treat retinal sarcoma and other types of retinal neoplasms.
4. Surgery: In some cases, surgery may be necessary to remove the tumor. This can involve removing the affected eye (enucleation) or removing only the tumor and a small amount of surrounding tissue (vitrectomy).
5. Chemotherapy: This is a treatment that uses drugs to kill cancer cells. It may be used in combination with other treatments, such as photocoagulation or surgery, to treat retinal neoplasms.

It is important to note that early detection and treatment of retinal neoplasms can help preserve vision and improve outcomes. If you experience any symptoms of a retinal tumor, such as blurred vision, flashes of light, or floaters, it is important to see an eye doctor as soon as possible for an evaluation.

There are several subtypes of lymphoma, B-cell, including:

1. Diffuse large B-cell lymphoma (DLBCL): This is the most common type of B-cell lymphoma and typically affects older adults.
2. Follicular lymphoma: This type of lymphoma grows slowly and often does not require treatment for several years.
3. Marginal zone lymphoma: This type of lymphoma develops in the marginal zone of the spleen or other lymphoid tissues.
4. Hodgkin lymphoma: This is a type of B-cell lymphoma that is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope.

The symptoms of lymphoma, B-cell can vary depending on the subtype and the location of the tumor. Common symptoms include swollen lymph nodes, fatigue, fever, night sweats, and weight loss.

Treatment for lymphoma, B-cell usually involves chemotherapy, which is a type of cancer treatment that uses drugs to kill cancer cells. Radiation therapy may also be used in some cases. In some cases, bone marrow or stem cell transplantation may be recommended.

Prognosis for lymphoma, B-cell depends on the subtype and the stage of the disease at the time of diagnosis. In general, the prognosis is good for patients with early-stage disease, but the cancer can be more difficult to treat if it has spread to other parts of the body.

Prevention of lymphoma, B-cell is not possible, as the exact cause of the disease is not known. However, avoiding exposure to certain risk factors, such as viral infections and pesticides, may help reduce the risk of developing the disease. Early detection and treatment can also improve outcomes for patients with lymphoma, B-cell.

Lymphoma, B-cell is a type of cancer that affects the immune system and can be treated with chemotherapy and other therapies. The prognosis varies depending on the subtype and stage of the disease at diagnosis. Prevention is not possible, but early detection and treatment can improve outcomes for patients with this condition.

The term anticipatory vomiting is used to describe the phenomenon where an individual experiences nausea and vomiting before undergoing a medical procedure, taking medication, or experiencing certain types of stimuli. The exact cause of anticipatory vomiting is not fully understood, but it is thought to be related to the activation of the brain's fear and anxiety centers.

Anticipatory vomiting can be caused by a variety of factors, including:

1. Previous negative experiences: Individuals who have experienced negative events or procedures in the past may anticipate similar experiences in the future and exhibit symptoms of anticipatory vomiting.
2. Fear and anxiety: The anticipation of a potentially unpleasant experience can cause individuals to feel anxious and fearful, which can lead to nausea and vomiting.
3. Conditioning: Classical conditioning, a psychological phenomenon where an individual learns to associate certain stimuli with negative outcomes, can contribute to the development of anticipatory vomiting.
4. Medical conditions: Certain medical conditions, such as migraines or motion sickness, can trigger anticipatory vomiting.
5. Medications: Some medications can cause nausea and vomiting as a side effect, which can lead to anticipatory vomiting in individuals who anticipate taking these medications.

The diagnosis of anticipatory vomiting typically involves a comprehensive medical history and physical examination to rule out other potential causes of the symptoms. Treatment for anticipatory vomiting may include:

1. Anti-anxiety medication: Medications such as benzodiazepines or selective serotonin reuptake inhibitors (SSRIs) can help reduce anxiety and alleviate symptoms of anticipatory vomiting.
2. Cognitive behavioral therapy (CBT): CBT can help individuals identify and change negative thought patterns and behaviors that contribute to anticipatory vomiting.
3. Relaxation techniques: Techniques such as deep breathing, progressive muscle relaxation, and mindfulness meditation can help individuals manage anxiety and reduce the likelihood of anticipatory vomiting.
4. Desensitization therapy: This type of therapy involves gradually exposing individuals to the feared situation or stimulus in a controlled and safe environment to help them become desensitized to their fears.
5. Avoiding triggers: Identifying and avoiding triggers for anticipatory vomiting, such as certain situations or medications, can help manage symptoms.

In summary, anticipatory vomiting is a condition where individuals experience nausea and vomiting in anticipation of a potentially unpleasant experience. It can be caused by a variety of factors, including psychological and medical conditions, and treated with a combination of medications, therapy, and lifestyle changes.

Symptoms of cerebellar neoplasms can include:

* Headaches
* Nausea and vomiting
* Dizziness and loss of balance
* Weakness or paralysis in the arms or legs
* Coordination problems and difficulty walking
* Double vision or other visual disturbances
* Speech difficulties
* Seizures

Cerebellar neoplasms can be caused by genetic mutations, exposure to radiation, or viral infections. They can also occur spontaneously without any known cause.

Diagnosis of cerebellar neoplasms usually involves a combination of imaging tests such as CT or MRI scans, and tissue sampling through biopsy. Treatment options for cerebellar neoplasms depend on the type, size, and location of the tumor, as well as the patient's overall health.

Treatment options may include:

* Surgery to remove the tumor
* Radiation therapy to kill remaining cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules that are involved in the growth and spread of the tumor.

Prognosis for cerebellar neoplasms varies depending on the type, size, and location of the tumor, as well as the patient's overall health. In general, the prognosis is better for patients with benign tumors that are located in the outer layers of the cerebellum, and worse for those with malignant tumors that are located in the deeper layers.

Overall, cerebellar neoplasms are a complex and rare type of brain tumor that require specialized care and treatment from a team of medical professionals.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

Examples of 'Mammary Neoplasms, Experimental' in a sentence:

1. The researchers studied the effects of hormone therapy on mammary neoplasms in experimental animals to better understand its potential role in human breast cancer.
2. The lab used mice with genetic mutations that predispose them to developing mammary neoplasms to test the efficacy of new cancer drugs.
3. In order to investigate the link between obesity and breast cancer, the researchers conducted experiments on mammary neoplasms in rats with diet-induced obesity.

There are several types of skin neoplasms, including:

1. Basal cell carcinoma (BCC): This is the most common type of skin cancer, and it usually appears as a small, fleshy bump or a flat, scaly patch. BCC is highly treatable, but if left untreated, it can grow and invade surrounding tissue.
2. Squamous cell carcinoma (SCC): This type of skin cancer is less common than BCC but more aggressive. It typically appears as a firm, flat, or raised bump on sun-exposed areas. SCC can spread to other parts of the body if left untreated.
3. Melanoma: This is the most serious type of skin cancer, accounting for only 1% of all skin neoplasms but responsible for the majority of skin cancer deaths. Melanoma can appear as a new or changing mole, and it's essential to recognize the ABCDE signs (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving size, shape, or color) to detect it early.
4. Sebaceous gland carcinoma: This rare type of skin cancer originates in the oil-producing glands of the skin and can appear as a firm, painless nodule on the forehead, nose, or other oily areas.
5. Merkel cell carcinoma: This is a rare and aggressive skin cancer that typically appears as a firm, shiny bump on the skin. It's more common in older adults and those with a history of sun exposure.
6. Cutaneous lymphoma: This type of cancer affects the immune system and can appear as a rash, nodules, or tumors on the skin.
7. Kaposi sarcoma: This is a rare type of skin cancer that affects people with weakened immune systems, such as those with HIV/AIDS. It typically appears as a flat, red or purple lesion on the skin.

While skin cancers are generally curable when detected early, it's important to be aware of your skin and notice any changes or unusual spots, especially if you have a history of sun exposure or other risk factors. If you suspect anything suspicious, see a dermatologist for an evaluation and potential biopsy. Remember, prevention is key to avoiding the harmful effects of UV radiation and reducing your risk of developing skin cancer.

There are different types of fever, including:

1. Pyrexia: This is the medical term for fever. It is used to describe a body temperature that is above normal, usually above 38°C (100.4°F).
2. Hyperthermia: This is a more severe form of fever, where the body temperature rises significantly above normal levels.
3. Febrile seizure: This is a seizure that occurs in children who have a high fever.
4. Remittent fever: This is a type of fever that comes and goes over a period of time.
5. Intermittent fever: This is a type of fever that recurs at regular intervals.
6. Chronic fever: This is a type of fever that persists for an extended period of time, often more than 3 weeks.

The symptoms of fever can vary depending on the underlying cause, but common symptoms include:

* Elevated body temperature
* Chills
* Sweating
* Headache
* Muscle aches
* Fatigue
* Loss of appetite

In some cases, fever can be a sign of a serious underlying condition, such as pneumonia, meningitis, or sepsis. It is important to seek medical attention if you or someone in your care has a fever, especially if it is accompanied by other symptoms such as difficulty breathing, confusion, or chest pain.

Treatment for fever depends on the underlying cause and the severity of the symptoms. In some cases, medication such as acetaminophen (paracetamol) or ibuprofen may be prescribed to help reduce the fever. It is important to follow the recommended dosage instructions carefully and to consult with a healthcare professional before giving medication to children.

In addition to medication, there are other ways to help manage fever symptoms at home. These include:

* Drinking plenty of fluids to stay hydrated
* Taking cool baths or using a cool compress to reduce body temperature
* Resting and avoiding strenuous activities
* Using over-the-counter pain relievers, such as acetaminophen (paracetamol) or ibuprofen, to help manage headache and muscle aches.

Preventive measures for fever include:

* Practicing good hygiene, such as washing your hands frequently and avoiding close contact with people who are sick
* Staying up to date on vaccinations, which can help prevent certain infections that can cause fever.

Examples of abdominal neoplasms include:

1. Colorectal cancer: A type of cancer that originates in the colon or rectum.
2. Stomach cancer: A type of cancer that originates in the stomach.
3. Small intestine cancer: A type of cancer that originates in the small intestine.
4. Liver cancer: A type of cancer that originates in the liver.
5. Pancreatic cancer: A type of cancer that originates in the pancreas.
6. Kidney cancer: A type of cancer that originates in the kidneys.
7. Adrenal gland cancer: A type of cancer that originates in the adrenal glands.
8. Gastrointestinal stromal tumors (GISTs): A type of tumor that originates in the digestive system, often in the stomach or small intestine.
9. Leiomyosarcoma: A type of cancer that originates in the smooth muscle tissue of the abdominal organs.
10. Lymphoma: A type of cancer that originates in the immune system and can affect the abdominal organs.

Abdominal neoplasms can cause a wide range of symptoms, including abdominal pain, weight loss, fatigue, and changes in bowel movements. Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and endoscopy, along with biopsies to confirm the presence of cancerous cells. Treatment options for abdominal neoplasms depend on the type and location of the tumor, and may include surgery, chemotherapy, radiation therapy, or a combination of these.

There are several types of trophoblastic neoplasms, including:

1. Hydatidiform mole (also known as a molar pregnancy): This is a benign tumor that develops from the placental cells and can cause symptoms such as vaginal bleeding, abdominal pain, and rapid growth of the uterus.
2. Invasive mole: This is a rare type of trophoblastic neoplasm that can invade nearby tissues and organs, and it has the potential to become a more aggressive and malignant form of cancer called choriocarcinoma.
3. Choriocarcinoma: This is a malignant tumor that originates from the placental cells and can spread to other parts of the body, such as the lungs, liver, and bones. It is a rare form of cancer, but it is highly aggressive and can be difficult to treat.
4. Placental-site trophoblastic tumors (PSTTs): These are rare tumors that develop at the site where the placenta attaches to the uterus. They can be benign or malignant, and they can invade nearby tissues and organs.

The symptoms of trophoblastic neoplasms can vary depending on the type and location of the tumor. Some common symptoms include:

* Vaginal bleeding or spotting
* Abdominal pain or cramping
* Rapid growth of the uterus
* Weakness and fatigue
* Nausea and vomiting
* Pelvic pressure or discomfort

The diagnosis of trophoblastic neoplasms is based on a combination of imaging studies, such as ultrasound and CT scans, and tissue sampling, such as biopsy or hysterectomy. Treatment options for trophoblastic neoplasms depend on the type and stage of the disease, but may include:

* Surgery to remove the tumor and any affected tissues
* Chemotherapy to kill cancer cells
* Radiation therapy to destroy cancer cells
* Hormone therapy to stop the growth of hormones that support the tumor.

Glioblastomas are highly malignant tumors that can grow rapidly and infiltrate surrounding brain tissue, making them difficult to remove surgically. They often recur after treatment and are usually fatal within a few years of diagnosis.

The symptoms of glioblastoma can vary depending on the location and size of the tumor but may include headaches, seizures, weakness or numbness in the arms or legs, and changes in personality, memory or cognitive function.

Glioblastomas are diagnosed through a combination of imaging tests such as CT or MRI scans, and a biopsy to confirm the presence of cancerous cells. Treatment typically involves surgery to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy to slow the growth of any remaining cancerous cells.

Prognosis for glioblastoma is generally poor, with a five-year survival rate of around 5% for newly diagnosed patients. However, the prognosis can vary depending on factors such as the location and size of the tumor, the patient's age and overall health, and the effectiveness of treatment.

There are several risk factors for developing HCC, including:

* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity

HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:

* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss

If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:

* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope

Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:

* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer

Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.

There are many different types of anemia, each with its own set of causes and symptoms. Some common types of anemia include:

1. Iron-deficiency anemia: This is the most common type of anemia and is caused by a lack of iron in the diet or a problem with the body's ability to absorb iron. Iron is essential for making hemoglobin.
2. Vitamin deficiency anemia: This type of anemia is caused by a lack of vitamins, such as vitamin B12 or folate, that are necessary for red blood cell production.
3. Anemia of chronic disease: This type of anemia is seen in people with chronic diseases, such as kidney disease, rheumatoid arthritis, and cancer.
4. Sickle cell anemia: This is a genetic disorder that affects the structure of hemoglobin and causes red blood cells to be shaped like crescents or sickles.
5. Thalassemia: This is a genetic disorder that affects the production of hemoglobin and can cause anemia, fatigue, and other health problems.

The symptoms of anemia can vary depending on the type and severity of the condition. Common symptoms include fatigue, weakness, pale skin, shortness of breath, and dizziness or lightheadedness. Anemia can be diagnosed with a blood test that measures the number and size of red blood cells, as well as the levels of hemoglobin and other nutrients.

Treatment for anemia depends on the underlying cause of the condition. In some cases, dietary changes or supplements may be sufficient to treat anemia. For example, people with iron-deficiency anemia may need to increase their intake of iron-rich foods or take iron supplements. In other cases, medical treatment may be necessary to address underlying conditions such as kidney disease or cancer.

Preventing anemia is important for maintaining good health and preventing complications. To prevent anemia, it is important to eat a balanced diet that includes plenty of iron-rich foods, vitamin C-rich foods, and other essential nutrients. It is also important to avoid certain substances that can interfere with the absorption of nutrients, such as alcohol and caffeine. Additionally, it is important to manage any underlying medical conditions and seek medical attention if symptoms of anemia persist or worsen over time.

In conclusion, anemia is a common blood disorder that can have significant health implications if left untreated. It is important to be aware of the different types of anemia, their causes, and symptoms in order to seek medical attention if necessary. With proper diagnosis and treatment, many cases of anemia can be successfully managed and prevented.

Transitional cell carcinoma typically affects older adults, with the average age at diagnosis being around 70 years. Men are more likely to be affected than women, and the risk of developing TCC increases with age and exposure to certain environmental factors such as smoking and exposure to certain chemicals.

The symptoms of TCC can vary depending on the location and stage of the cancer, but may include:

* Blood in the urine (hematuria)
* Painful urination
* Frequent urination
* Pain in the lower abdomen or back

If left untreated, TCC can spread to other parts of the body, including the lymph nodes, liver, and bones. Treatment options for TCC may include surgery, chemotherapy, and immunotherapy, and the prognosis depends on the stage and location of the cancer at the time of diagnosis.

Preventive measures to reduce the risk of developing TCC include maintaining a healthy diet and lifestyle, avoiding smoking and excessive alcohol consumption, and regular screening for bladder cancer. Early detection and treatment can improve the prognosis for patients with TCC.

There are several types of radiation injuries, including:

1. Acute radiation syndrome (ARS): This occurs when a person is exposed to a high dose of ionizing radiation over a short period of time. Symptoms can include nausea, vomiting, diarrhea, fatigue, and damage to the bone marrow, lungs, and gastrointestinal system.
2. Chronic radiation syndrome: This occurs when a person is exposed to low levels of ionizing radiation over a longer period of time. Symptoms can include fatigue, skin changes, and an increased risk of cancer.
3. Radiation burns: These are similar to thermal burns, but are caused by the heat generated by ionizing radiation. They can cause skin damage, blistering, and scarring.
4. Ocular radiation injury: This occurs when the eyes are exposed to high levels of ionizing radiation, leading to damage to the retina and other parts of the eye.
5. Radiation-induced cancer: Exposure to high levels of ionizing radiation can increase the risk of developing cancer, particularly leukemia and other types of cancer that affect the bone marrow.

Radiation injuries are diagnosed based on a combination of physical examination, medical imaging (such as X-rays or CT scans), and laboratory tests. Treatment depends on the type and severity of the injury, but may include supportive care, medication, and radiation therapy to prevent further damage.

Preventing radiation injuries is important, especially in situations where exposure to ionizing radiation is unavoidable, such as in medical imaging or nuclear accidents. This can be achieved through the use of protective shielding, personal protective equipment, and strict safety protocols.

The symptoms of oligodendroglioma can vary depending on the location and size of the tumor, but may include headaches, seizures, weakness or numbness in the arms or legs, and changes in personality or behavior.

Oligodendrogliomas are diagnosed through a combination of imaging tests such as MRI or CT scans, and tissue biopsy. Treatment options for oligodendroglioma can include surgery to remove the tumor, radiation therapy, and chemotherapy with drugs such as temozolomide.

Prognosis for oligodendroglioma depends on the location, size, and aggressiveness of the tumor, as well as the age and overall health of the patient. In general, benign oligodendrogliomas have a good prognosis, while malignant ones are more difficult to treat and can be associated with a poorer outcome.

There is ongoing research into new treatments for oligodendroglioma, including clinical trials of innovative drugs and therapies.

Ewing's sarcoma is a rare and aggressive type of cancer that affects the bones and soft tissues of the body. It primarily occurs in the pelvis, spine, and limbs. This malignancy usually develops in children and young adults between the ages of 10 and 30.

Ewing's sarcoma is caused by a genetic mutation in the EWS gene, which is responsible for regulating cell growth and division. The mutated gene leads to uncontrollable cell proliferation, resulting in the formation of a tumor.

The symptoms of Ewing's sarcoma vary depending on the location of the tumor but can include pain, swelling, limited mobility, and broken bones. Diagnosis is usually made through a combination of imaging tests such as X-rays, CT scans, and PET scans, along with a biopsy to confirm the presence of cancer cells.

Treatment for Ewing's sarcoma typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery is used to remove the tumor and any affected tissue, while chemotherapy and radiation therapy are used to kill any remaining cancer cells. The prognosis for Ewing's sarcoma varies depending on the stage and location of the cancer but can be improved with early diagnosis and appropriate treatment.

1. Tumor size and location: Larger tumors that have spread to nearby tissues or organs are generally considered more invasive than smaller tumors that are confined to the original site.
2. Cellular growth patterns: The way in which cancer cells grow and divide can also contribute to the overall invasiveness of a neoplasm. For example, cells that grow in a disorganized or chaotic manner may be more likely to invade surrounding tissues.
3. Mitotic index: The mitotic index is a measure of how quickly the cancer cells are dividing. A higher mitotic index is generally associated with more aggressive and invasive cancers.
4. Necrosis: Necrosis, or the death of cells, can be an indication of the level of invasiveness of a neoplasm. The presence of significant necrosis in a tumor is often a sign that the cancer has invaded surrounding tissues and organs.
5. Lymphovascular invasion: Cancer cells that have invaded lymphatic vessels or blood vessels are considered more invasive than those that have not.
6. Perineural invasion: Cancer cells that have invaded nerve fibers are also considered more invasive.
7. Histological grade: The histological grade of a neoplasm is a measure of how abnormal the cancer cells look under a microscope. Higher-grade cancers are generally considered more aggressive and invasive than lower-grade cancers.
8. Immunohistochemical markers: Certain immunohistochemical markers, such as Ki-67, can be used to evaluate the proliferative activity of cancer cells. Higher levels of these markers are generally associated with more aggressive and invasive cancers.

Overall, the degree of neoplasm invasiveness is an important factor in determining the likelihood of the cancer spreading to other parts of the body (metastasizing) and in determining the appropriate treatment strategy for the patient.

The symptoms of retinoblastoma can vary depending on the location and size of the tumor, but may include:

* A white or colored mass in one eye
* Redness or swelling of the eye
* Sensitivity to light
* Blurred vision or vision loss
* Crossed eyes (strabismus)
* Eye pain or discomfort

Retinoblastoma is usually diagnosed with a combination of physical examination, imaging tests such as ultrasound and MRI, and genetic testing. Treatment options depend on the stage and location of the tumor, but may include:

* Chemotherapy to shrink the tumor before surgery
* Surgery to remove the tumor and/or the affected eye (enucleation)
* Radiation therapy to kill any remaining cancer cells
* Targeted therapy with drugs that specifically target cancer cells

The prognosis for retinoblastoma depends on the stage of the disease at diagnosis. If the tumor is confined to one eye and has not spread to other parts of the body, the 5-year survival rate is high (around 90%). However, if the tumor has spread to other parts of the body (known as metastatic retinoblastoma), the prognosis is much poorer.

Retinoblastoma can be inherited in an autosomal dominant pattern, meaning that a single copy of the mutated RB1 gene is enough to cause the condition. Families with a history of retinoblastoma may undergo genetic testing and counseling to determine their risk of developing the disease.

The exact cause of RMS is not known, but it is believed to be linked to genetic mutations that occur during fetal development. These mutations can lead to the growth of abnormal cells that can eventually form a tumor.

There are several subtypes of RMS, including:

1. Embryonal rhabdomyosarcoma: This is the most common type of RMS and typically affects children under the age of 6.
2. Alveolar rhabdomyosarcoma: This type of RMS is more aggressive than embryonal RMS and tends to affect older children and teenagers.
3. Pleomorphic rhabdomyosarcoma: This is the least common subtype of RMS and can occur in any age group.

The symptoms of RMS vary depending on the location of the tumor, but may include:

* Lumps or swelling in the neck, abdomen, or extremities
* Painless lumps or swelling in the scrotum (in boys)
* Difficulty swallowing or breathing (if the tumor is located in the throat)
* Abdominal pain (if the tumor is located in the abdomen)
* Fever
* Fatigue
* Weight loss

If RMS is suspected, a doctor may perform a physical exam, take a medical history, and order imaging tests such as X-rays, CT scans, or MRI scans to confirm the diagnosis. A biopsy, in which a small sample of tissue is removed from the body and examined under a microscope, may also be performed to confirm the presence of cancer cells.

Treatment for RMS typically involves a combination of surgery, chemotherapy, and radiation therapy. The specific treatment plan will depend on the location and size of the tumor, as well as the age and overall health of the patient. In some cases, the tumor may be completely removed with surgery, while in other cases, the cancer cells may be difficult to remove and may require ongoing treatment to manage the disease.

Overall, RMS is a rare and aggressive form of cancer that can affect children and adults. While the prognosis for RMS varies depending on the location and size of the tumor, early diagnosis and treatment are critical for improving outcomes.

Common types of genital neoplasms in females include:

1. Vulvar intraepithelial neoplasia (VIN): A precancerous condition that affects the vulva, the external female genital area.
2. Cervical dysplasia: Precancerous changes in the cells of the cervix, which can progress to cancer if left untreated.
3. Endometrial hyperplasia: Abnormal growth of the uterine lining, which can sometimes develop into endometrial cancer.
4. Endometrial adenocarcinoma: Cancer that arises in the glands of the uterine lining.
5. Ovarian cancer: Cancer that originates in the ovaries.
6. Vaginal cancer: Cancer that occurs in the vagina.
7. Cervical cancer: Cancer that occurs in the cervix.
8. Uterine leiomyosarcoma: A rare type of cancer that occurs in the uterus.
9. Uterine clear cell carcinoma: A rare type of cancer that occurs in the uterus.
10. Mesothelioma: A rare type of cancer that affects the lining of the abdominal cavity, including the female reproductive organs.

Treatment for genital neoplasms in females depends on the type and stage of the disease, and may include surgery, radiation therapy, chemotherapy, or a combination of these. Early detection and treatment are important to improve outcomes and reduce the risk of complications.

1. Leukemia: A type of cancer that affects the blood and bone marrow, characterized by an overproduction of immature white blood cells.
2. Lymphoma: A type of cancer that affects the immune system, often involving the lymph nodes and other lymphoid tissues.
3. Multiple myeloma: A type of cancer that affects the plasma cells in the bone marrow, leading to an overproduction of abnormal plasma cells.
4. Myelodysplastic syndrome (MDS): A group of disorders characterized by the impaired development of blood cells in the bone marrow.
5. Osteopetrosis: A rare genetic disorder that causes an overgrowth of bone, leading to a thickened bone marrow.
6. Bone marrow failure: A condition where the bone marrow is unable to produce enough blood cells, leading to anemia, infection, and other complications.
7. Myelofibrosis: A condition characterized by the scarring of the bone marrow, which can lead to an overproduction of blood cells and an increased risk of bleeding and infection.
8. Polycythemia vera: A rare blood disorder that causes an overproduction of red blood cells, leading to an increased risk of blood clots and other complications.
9. Essential thrombocythemia: A rare blood disorder that causes an overproduction of platelets, leading to an increased risk of blood clots and other complications.
10. Myeloproliferative neoplasms (MPNs): A group of rare blood disorders that are characterized by the overproduction of blood cells and an increased risk of bleeding and infection.

These are just a few examples of bone marrow diseases. There are many other conditions that can affect the bone marrow, and each one can have a significant impact on a person's quality of life. If you suspect that you or someone you know may have a bone marrow disease, it is important to seek medical attention as soon as possible. A healthcare professional can perform tests and provide a proper diagnosis and treatment plan.

Biliary tract neoplasms refer to abnormal growths or tumors that occur in the biliary tract, which includes the liver, gallbladder, and bile ducts. These tumors can be benign (non-cancerous) or malignant (cancerous).

There are several types of biliary tract neoplasms, including:

1. Cholangiocarcinoma: This is a rare type of cancer that originates in the cells lining the bile ducts. It can occur in the liver or outside the liver.
2. Gallbladder cancer: This type of cancer occurs in the gallbladder and is relatively rare.
3. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer, which means it originates in the liver rather than spreading from another part of the body.
4. Bile duct cancer: This type of cancer occurs in the bile ducts that carry bile from the liver and gallbladder to the small intestine.

Biliary tract neoplasms can cause a variety of symptoms, including abdominal pain, jaundice (yellowing of the skin and eyes), weight loss, fatigue, and itching. These symptoms can be non-specific and may resemble those of other conditions, making diagnosis challenging.

Diagnosis of biliary tract neoplasms usually involves a combination of imaging tests such as ultrasound, CT scans, MRI, and PET scans, as well as biopsies to confirm the presence of cancer cells. Treatment options for biliary tract neoplasms depend on the type, size, location, and stage of the tumor, and may include surgery, chemotherapy, radiation therapy, or a combination of these.

Source: National Cancer Institute (www.cancer.gov)

The above definition is given by the National Cancer Institute, which is an authoritative source of information on cancer and lymphoma. It provides a concise overview of follicular lymphoma, including its characteristics, diagnosis, treatment options, and prognosis. The definition includes key terms such as "slow-growing," "B cells," "lymph nodes," and "five-year survival rate," which are important to understand when discussing this type of cancer.

The exact cause of hepatoblastoma is not known, but it is believed to be linked to genetic mutations that occur during fetal development. Children with certain congenital conditions, such as Beckwith-Wiedemann syndrome, are at higher risk of developing hepatoblastoma. The symptoms of hepatoblastoma can include abdominal pain, weight loss, and jaundice (yellowing of the skin and eyes), but in many cases, the cancer may not cause any noticeable symptoms until it has reached an advanced stage.

Hepatoblastoma is diagnosed through a combination of imaging tests, such as ultrasound, CT scans, and MRI, and a biopsy to confirm the presence of cancer cells. Treatment typically involves surgery to remove the affected lobe of the liver, followed by chemotherapy to kill any remaining cancer cells. In some cases, a liver transplant may be necessary if the cancer has spread too far or if the child's liver is not functioning properly. The prognosis for hepatoblastoma depends on several factors, including the stage of the cancer at diagnosis and the effectiveness of treatment. With current treatments, the 5-year survival rate for children with hepatoblastoma is around 70%.

There are several types of muscle neoplasms, including:

1. Leiomyoma: A benign tumor that develops in the smooth muscle tissue of the uterus. It is the most common type of uterine tumor and is usually found in women over the age of 30.
2. Rhabdomyosarcoma: A rare type of cancerous muscle tumor that can develop in children and young adults. It can occur in any part of the body, but is most commonly found in the head, neck, or genitourinary tract.
3. Liposarcoma: A rare type of cancerous muscle tumor that develops in the fat cells of the soft tissue. It can occur in any part of the body and is more common in older adults.
4. Fibromyxoid tumor: A rare benign tumor that develops in the muscles and connective tissue. It usually affects the arms or legs and can be diagnosed at any age, but is most commonly found in children and young adults.
5. Alveolar soft part sarcoma: A rare type of cancerous muscle tumor that develops in the soft tissue of the body. It is more common in younger adults and can occur anywhere in the body, but is most commonly found in the legs or arms.

The symptoms of muscle neoplasms vary depending on the location and size of the tumor. They may include pain, swelling, redness, and limited mobility in the affected area. Diagnosis is usually made through a combination of imaging tests such as X-rays, CT scans, or MRI, and a biopsy to confirm the presence of cancerous cells.

Treatment for muscle neoplasms depends on the type and location of the tumor, as well as the stage of the disease. Surgery is often the first line of treatment, followed by radiation therapy or chemotherapy if the tumor is malignant. In some cases, observation and monitoring may be recommended if the tumor is benign and not causing any symptoms.

It's important to note that muscle neoplasms are relatively rare, and most muscle masses are benign and non-cancerous. However, it's always best to consult a medical professional if you notice any unusual lumps or bumps on your body to determine the cause and appropriate treatment.

SCLC typically starts in the bronchi of the lungs and can spread quickly to other parts of the body, such as the brain, liver, and bones. It is often found in later stages and is associated with a poorer prognosis than non-small cell lung cancer (NSCLC).

There are two main types of SCLC:

1. Limited-stage SCLC: This type of SCLC is limited to one lung and has not spread to other parts of the body.
2. Extensive-stage SCLC: This type of SCLC has spread beyond one lung and may have spread to other parts of the body.

Symptoms of SCLC include:

* Coughing
* Chest pain
* Shortness of breath
* Weight loss
* Fatigue

Diagnosis of SCLC is typically made through a combination of imaging tests, such as chest X-rays, CT scans, and PET scans, and a biopsy to confirm the presence of cancer cells. Treatment options for SCLC include:

1. Chemotherapy: This is the primary treatment for SCLC and may be used alone or in combination with radiation therapy.
2. Radiation therapy: This may be used alone or in combination with chemotherapy to treat SCLC.
3. Surgery: In some cases, surgery may be possible to remove the tumor and affected tissue.
4. Clinical trials: These may be available for patients with SCLC to access new and innovative treatments.

Overall, SCLC is a highly aggressive form of lung cancer that requires prompt and accurate diagnosis and treatment to improve outcomes.

1. Alopecia areata: This is an autoimmune disorder that causes patchy hair loss on the scalp or body.
2. Androgenetic alopecia (male pattern baldness): This is a common condition in which men experience hair loss due to hormonal changes.
3. Telogen effluvium: This is a condition where there is an increase in the number of hair follicles that stop growing and enter the resting phase, leading to excessive hair shedding.
4. Alopecia totalis: This is a condition where all hair on the scalp is lost, including eyebrows and lashes.
5. Alopecia universalis: This is a condition where all body hair is lost.

Alopecia can be caused by a variety of factors, including genetics, hormonal imbalances, autoimmune disorders, and certain medications. Treatment options for alopecia depend on the underlying cause and may include medications, hair transplantation, or other therapies.

In medical literature, alopecia is often used as a term to describe the loss of hair in specific contexts, such as in the treatment of cancer patients or in the management of autoimmune disorders. It is also used to describe the side effects of certain medications, such as chemotherapy drugs that can cause hair loss.

The exact cause of ductal carcinoma is unknown, but certain risk factors such as family history, genetics, hormone replacement therapy, obesity, and delayed childbearing have been linked to its development. Early detection through mammography and breast self-examination can improve survival rates, which are generally high for women diagnosed with this type of cancer if caught early. Treatment typically involves surgery to remove the tumor (lumpectomy or mastectomy), followed by radiation therapy and/or chemotherapy.

Necrosis is a type of cell death that occurs when cells are exposed to excessive stress, injury, or inflammation, leading to damage to the cell membrane and the release of cellular contents into the surrounding tissue. This can lead to the formation of gangrene, which is the death of body tissue due to lack of blood supply.

There are several types of necrosis, including:

1. Coagulative necrosis: This type of necrosis occurs when there is a lack of blood supply to the tissues, leading to the formation of a firm, white plaque on the surface of the affected area.
2. Liquefactive necrosis: This type of necrosis occurs when there is an infection or inflammation that causes the death of cells and the formation of pus.
3. Caseous necrosis: This type of necrosis occurs when there is a chronic infection, such as tuberculosis, and the affected tissue becomes soft and cheese-like.
4. Fat necrosis: This type of necrosis occurs when there is trauma to fatty tissue, leading to the formation of firm, yellowish nodules.
5. Necrotizing fasciitis: This is a severe and life-threatening form of necrosis that affects the skin and underlying tissues, often as a result of bacterial infection.

The diagnosis of necrosis is typically made through a combination of physical examination, imaging studies such as X-rays or CT scans, and laboratory tests such as biopsy. Treatment depends on the underlying cause of the necrosis and may include antibiotics, surgical debridement, or amputation in severe cases.

... antineoplastic combined chemotherapy protocols MeSH E02.190.044.080 - acupressure MeSH E02.190.044.105 - acupuncture analgesia ... antineoplastic combined chemotherapy protocols MeSH E02.319.162.150 - antibiotic prophylaxis MeSH E02.319.300.253 - delayed- ... antineoplastic combined chemotherapy protocols MeSH E02.319.310.075 - antiretroviral therapy, highly active MeSH E02.319. ...
The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible ... G-CSF is still included, even though the "G" is taken out of the acronym.) Amsacrine is an alkylating antineoplastic agent that ... In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan ... FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). The acronym incorporates the ...
using Metronomic chemotherapy in advanced pediatric malignancies: a multicenter experience. Oncology. 2012;82(5):249-60. doi: ... CUSP9 [Coordinated Undermining of Survival Paths] is one of several cancer treatment protocols using re-purposed older drugs to ... A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. ... Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug ...
This type of chemotherapy is used for curative intent.: 55-59 Combined modality chemotherapy is the use of drugs with other ... In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, and the American Society of Health-System ... Generating Inhibitors of P-Glycoprotein: Where to, Now?. Springer Protocols. pp. 405-432. Luqmani YA (2005). "Mechanisms of ... 59 Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy ...
Aprepitant combined with ondansetron and dexamethasone has been shown to be better for highly emetogenic chemotherapy than just ... The new protocol that he developed led to a marked increase in disease-free survival rates for patients with medulloblastoma, ... Cisplatin is in the platinum-based antineoplastic family of medications. It works in part by binding to DNA and inhibiting its ... Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, ...
... treatment with combined radiotherapy and chemotherapy improves survival significantly. Chemotherapy for NSCLC usually includes ... with cisplatin or carboplatin as the backbone of all the chemotherapy treatments protocols. Pemetrexed is provided with ... and approved pembrolizumab in combination with pemetrexed and platinum-based antineoplastic (carboplatin or cisplatin) as first ... chemotherapy plus atezolizumab or chemotherapy plus Bevacizumab and atezolizumab. The chemotherapy used was Carboplatin, and ...
Helgstrand E, Oberg B (1980). "Enzymatic targets in virus chemotherapy". Virus Chemotherapy. Antibiotics and Chemotherapy. Vol ... This may also be combined with radioactivity to achieve apoptosis of malignant cells. Some antiviral drugs, such as acyclovir ( ... 2015). "Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2 ... Cold Spring Harbor Protocols. 2016 (2): pdb.prot085118. doi:10.1101/pdb.prot085118. PMID 26832684. Sun R, Eriksson S, Wang L ( ...
"The purine path to chemotherapy. Nobel Lecture 1988". Black J. "Drugs from emasculated hormones: the principles of synoptic ... Some descriptors such as ligand efficiency (LE) and lipophilic efficiency (LiPE) combine such parameters to assess druglikeness ... For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs, the numbers ... agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis". Bioorganic & Medicinal Chemistry Letters ...
The combined high prevalence of rates of aflatoxin and hepatitis B in settings such as China and West Africa has led to ... Mipsagargin (G-202), has orphan drug designation as a treatment during chemotherapy for HCC. It is a thapsigargin-based prodrug ... Controversy remains as to the most effective screening protocols. For example, while some data support decreased mortality ... "Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells". Biochemical ...
"Antineoplastic (Chemotherapy) Drugs - Reproductive Health , NIOSH , CDC". www.cdc.gov. 2022-02-02. Retrieved 2022-03-17. " ... The Maputo Protocol, which was adopted by the African Union in the form of a protocol to the African Charter on Human and ... The use of the birth control pill is common in western countries, and two forms of combined oral contraceptives are on the ... "Protocol to the African Charter on Human and Peoples' Rights on the Rights of Women in Africa". Legal Instruments. African ...
Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. ... Reilly DR, Delva NJ, Hudson RW (August 2000). "Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the ... 26-. ISBN 978-0-323-48408-4. Deleve, Laurie D. (2013). "Cancer Chemotherapy". Drug-Induced Liver Disease. pp. 541-567. doi: ... Hormonal antineoplastic drugs, Ketones, Pregnane X receptor agonists, Pregnanes, Progestogen esters, Progestogens, Prolactin ...
Antineoplastic Combined Chemotherapy Protocols ✖Remove constraint Subjects: Antineoplastic Combined Chemotherapy Protocols ... Antineoplastic Combined Chemotherapy Protocols. Drug Labeling -- legislation & jurisprudence. Government Regulation. United ... Antineoplastic Combined Chemotherapy Protocols✖[remove]1. *Drug Labeling -- legislation & jurisprudence1. *Government ...
The combined blockade of sonic hedgehog and mTOR signaling together with standard chemotherapy is capable of eliminating ... Antineoplastic Combined Chemotherapy Protocols / pharmacology* * Cell Line, Tumor * Deoxycytidine / analogs & derivatives * ... Only the combined inhibition of both pathways together with chemotherapy reduced the number of CSCs to virtually undetectable ... Conclusions: The combined blockade of sonic hedgehog and mTOR signaling together with standard chemotherapy is capable of ...
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Actions. * Search in PubMed * Search in MeSH ... Paclitaxel: a new antineoplastic agent for refractory ovarian cancer R E Gregory et al. Clin Pharm. 1993 Jun. ... Paclitaxel: a new antineoplastic agent for refractory ovarian cancer R E Gregory 1 , A F DeLisa ...
Antineoplastic Combined Chemotherapy Protocols. 1. 2018. 11236. 0.040. Why? Death. 1. 2021. 581. 0.040. Why? ...
Antineoplastic Combined Chemotherapy Protocols Actions. * Search in PubMed * Search in MeSH * Add to Search ... Polyphenol-based nanoplatform for MRI/PET dual-modality imaging guided effective combination chemotherapy Jingjing Wang 1 , Wei ... Polyphenol-based nanoplatform for MRI/PET dual-modality imaging guided effective combination chemotherapy Jingjing Wang et al. ... A Multi-Functional Tumor Theranostic Nanoplatform for MRI Guided Photothermal-Chemotherapy. Shi J, Wang B, Chen Z, Liu W, Pan J ...
MeSH Terms: Antineoplastic Combined Chemotherapy Protocols; Apoptosis/drug effects; Benzamides/pharmacology*; Blotting, Western ...
Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Actions. * Search in PubMed * Search in MeSH ... novel treatments or chemotherapy combinations have been able to improve these poor outcomes. Olaratumab is a human antiplatelet ...
"Antineoplastic Combined Chemotherapy Protocols" and to chemicals used in the protocols found in D tree descriptors. ... Class 2 Supplementary Records - Protocols. These records are dedicated to Chemotherapy Protocols. They are heading mapped to ... The first of these is coordination, the combined use of two or more separate descriptors. For example, jejunal enteritis may be ...
We treated the patient with 3 chemotherapy regimens, and he survived for almost 2 years after diagnosis.Conclusions:The ... Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma - metabolism ... Response to chemotherapy in a case of gastric adenocarcinoma producing granulocyte colony-stimulating factor Hiroki MoriABCDEF ... We treated the patient with 3 chemotherapy regimens, and he survived for almost 2 years after diagnosis.. Conclusions: The ...
Antineoplastic Drug Combinations Cancer Chemotherapy Protocols Chemotherapy Protocols, Antineoplastic Combined Antineoplastic ... Antineoplastic Agents, Combined Antineoplastic Chemotherapy Protocols Antineoplastic Combined Chemotherapy Regimens ... Clinical Protocols [E02.183] * Antineoplastic Protocols [E02.183.750] * Antineoplastic Combined Chemotherapy Protocols [E02.183 ... Antineoplastic Chemotherapy Protocols Broader Concept UI. M0369990. Terms. Antineoplastic Chemotherapy Protocols Preferred Term ...
Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; ... Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ...
Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms/drug therapy, Disease Progression, Double-Blind Method, Follow- ... Dive into the research topics of Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men ... These results further support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive ... These results further support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive ...
... showing publications Samuel Hellman has written about Antineoplastic Combined Chemotherapy Protocols. ... Samuel Hellman to Antineoplastic Combined Chemotherapy Protocols. Back to Details This is a "connection" page, ...
Antineoplastic Combined Chemotherapy Protocols, Maintenance Chemotherapy. UCL classification:. UCL. UCL , Provost and Vice ... We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD ... following platinum-based chemotherapy, extended PFS in DRD biomarker-selected patients with mUC and was tolerable. Further ... Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition with Rucaparib Following Chemotherapy for ...
Antineoplastic Drug Combinations Cancer Chemotherapy Protocols Chemotherapy Protocols, Antineoplastic Combined Antineoplastic ... Antineoplastic Agents, Combined Antineoplastic Chemotherapy Protocols Antineoplastic Combined Chemotherapy Regimens ... Clinical Protocols [E02.183] * Antineoplastic Protocols [E02.183.750] * Antineoplastic Combined Chemotherapy Protocols [E02.183 ... Antineoplastic Chemotherapy Protocols Broader Concept UI. M0369990. Terms. Antineoplastic Chemotherapy Protocols Preferred Term ...
Absorptiometry, Photon, Aged, Antineoplastic Combined Chemotherapy Protocols, Body Composition, Body Weight, Carcinoma, Small ... Making both ends neat: exploring the effects of modifying the TTO protocol on non-trading and all-in trading ...
Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; ... Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and ...
Antineoplastic Combined Chemotherapy Protocols. *Colorectal Neoplasms. *Trifluridine. Contact. Organisation Name: HAYES, Inc. ... TFD is an antineoplastic thymidine-based nucleoside analog that acts as a nucleoside metabolic inhibitor, and TPI is a ... and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and, if RAS (KRAS, ...
ABVD protocol; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Antigens, CD20; Clinical Trials as Topic ...
Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; ...
Combined Antiangiogenic Agents for Hepatocellular Carcinoma and (2) Immune Based Therapies for Gastrointestinal Malignancies ... Antineoplastic Combined Chemotherapy Protocols--therapeutic use. Carcinoma, Hepatocellular--drug therapy. Gastrointestinal ... Combined antiangiogenic agents for hepatocellular carcinoma / Austin Duffy. Immune based therapies for gastrointestinal ... CC Grand Rounds: (1) Combined Antiangiogenic Agents for Hepatocellular Carcinoma and (2) Immune Based Therapies for ...
MeSH Terms: Animals; Anticarcinogenic Agents/pharmacology*; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; ...
Antineoplastic Combined Chemotherapy Protocols / adverse effects Actions. * Search in PubMed * Search in MeSH ... Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated ... Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, ...
Antineoplastic Combined Chemotherapy Protocols Actions. * Search in PubMed * Search in MeSH * Add to Search ...
Combined. Antineoplastic Chemotherapy Protocol. Antineoplastic Chemotherapy Protocols. Antineoplastic Combined Chemotherapy ... Cancer Chemotherapy Protocol Cancer Chemotherapy Protocols Chemotherapy Protocol, Antineoplastic Chemotherapy Protocol, Cancer ... Chemotherapy Protocols, Antineoplastic Chemotherapy Protocols, Cancer Protocol, Antineoplastic Chemotherapy Protocol, Cancer ... Cancer Chemotherapy Protocol. Cancer Chemotherapy Protocols. Chemotherapy Protocol, Antineoplastic. Chemotherapy Protocol, ...
Palavras-chave : Antineoplastic Combined Chemotherapy Protocols; Mucositis; Laser Therapy; Low-level. · resumo em Português · ... Laserphototherapy on treatment of chemotherapy-induced oral mucositis: case report. Rev. Assoc. Paul. Cir. Dent. [online]. 2013 ... after 5-fluorouracil and cisplatin chemotherapy. A diode laser, 0.04 cm2 of spot area, 660nm, 40mW, 6J/cm2 and 0.24J per point ... is a debilitating acute inflammation of patients undergoing cancer therapy including high doses of chemotherapy or head and ...
Antineoplastic Combined Chemotherapy Protocols (38) * Neoplasms (34) * Carcinoma, Squamous Cell (32) * Antipsychotic Agents (31 ... PROTOCOLS OR db:COCHRANE-METH_REVIEWS OR db:COCHRANE-PROTOCOLS OR db:COCHRANE-REGISTRO OR db:COCHRANE-REVIEWS-PLUS OR ...
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III ... Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol ... A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone ... Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection ...
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III ... Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol ... A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone ... Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection ...
Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on ... DPM (50 microg) combined with silica (233 microg) increased inflammation at one week and one-month postexposure and caused an ... Many antineoplastic drugs used to treat cancer, particularly alkylating agents and topoisomerase inhibitors, are known to ... Methods: In data from a five-year study of school-based and village-wide preventive chemotherapy strategies for Schistosoma ...
... with head and neck cancer treated with radiotherapy combined or not with chemotherapy. Pesq Bras Odontoped Clin Integr. 2012;12 ... Adopting protocols for planning the oncological treatment, primarily focusing on control and careful oral hygiene before the ... The antineoplastic treatment, like chemotherapy, has the capacity to induce cellular damage in the epithelium, oral mucosa and ... Among antineoplastic treatment modalities, radiotherapy and chemotherapy, when performed mainly in the head and neck region, ...
Antineoplastic Agents. Antineoplastic agents most commonly associated with ototoxicity are the platinum-based compounds ... Some studies describe a hearing loss of 61% of children receiving platinum-based chemotherapy. [21] This is comparable with ... Cellular and subcellular localization of tritiated gentamicin in the guinea pig cochlea following combined treatment with ... that further investigation is warranted to define the role of sodium thiosulfate in cisplatin-based treatment protocols. [24] ...
Lotfy, M., Badra, G., Burham, W., and Alenzi, F. Q. Combined use of honey, bee propolis and myrrh in healing a deep, infected ... Swellam, T., Miyanaga, N., Onozawa, M., Hattori, K., Kawai, K., Shimazui, T., and Akaza, H. Antineoplastic activity of honey in ... Zidan, J., Shetver, L., Gershuny, A., Abzah, A., Tamam, S., Stein, M., and Friedman, E. Prevention of chemotherapy-induced ... The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for ...
Gemtuzumab ozogamicin (a CD33-directed antibody-drug conjugate) can be combined with chemotherapy in patients with newly ... Therapy-related AML (t-AML) is a subtype of AML caused by prior treatment with certain antineoplastic drugs (eg, alkylating ... Prognostic factors help determine treatment protocol and intensity; patients with strongly negative prognostic features are ... Treatment includes induction chemotherapy to achieve remission and postremission chemotherapy (with or without stem cell ...
  • High dose cisplatin (200 mg m-2) combined with etoposide (500 mg m-2), HIPE, was alternated with ifosfamide (9 g m-2), vincristine (1.5 mg m-2), and adriamycin (60 mg m-1), IVAd. (ox.ac.uk)
  • We treated the patient with 3 chemotherapy regimens, and he survived for almost 2 years after diagnosis. (medscimonit.com)
  • A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. (lookformedical.com)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • The distribution of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms was investigated in 80 consecutive breast cancer patients treated with adjuvant chemotherapy. (nih.gov)
  • 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
  • 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer. (cdc.gov)
  • These results further support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. (lu.se)
  • PURPOSE A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. (ucl.ac.uk)
  • Patient Population: TFD-TPI is used to treat adult patients with metastatic CRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and, if RAS (KRAS, HRAS, NRAS) wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. (inahta.org)
  • Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ox.ac.uk)
  • Fifty-one children, aged from 15 months to 13 years 5 months with metastatic neuroblastoma presenting sequentially at the participating institutions received four 3 to 4 weekly courses of high dose multiagent chemotherapy. (ox.ac.uk)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. (nih.gov)
  • In the design of new preoperative (neoadjuvant) chemotherapy trials, stratification of tumors by K-ras status deserves to be further investigated in order to correlate with response, relapse and survival. (ox.ac.uk)
  • Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. (liu.edu)
  • The primary goals of HSCT are either to replace haematopoietic stem and progenitor cel s (HSPC) following myeloablative chemotherapy or to cure the original pathology with allogeneic HSPCs. (who.int)
  • 238 (44%) patients initially receiving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per protocol (93 patients) or as subsequent therapy (145 patients). (lu.se)
  • We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker-positive mUC.METHODSDRD biomarker-positive mUC patients, within 10 weeks of chemotherapy, and without cancer progression, were randomly assigned (1:1) to maintenance rucaparib 600 mg twice a day orally, or placebo, until disease progression. (ucl.ac.uk)
  • Rinsing the mouth and then slowly swallowing honey before and after chemotherapy or radiation therapy sessions seems to reduce the risk of developing mouth sores. (medlineplus.gov)
  • BACKGROUND: Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. (lu.se)
  • TFD is an antineoplastic thymidine-based nucleoside analog that acts as a nucleoside metabolic inhibitor, and TPI is a thymidine phosphorylase inhibitor. (inahta.org)
  • Only the combined inhibition of both pathways together with chemotherapy reduced the number of CSCs to virtually undetectable levels in vitro and in vivo. (nih.gov)
  • 75 years old or who have comorbidities that would be prohibitive of intensive induction chemotherapy. (nih.gov)
  • FDA approval was based on a randomized, placebo-controlled, phase II trial in elderly or infirmed adults with new AML, unable to receive intensive induction chemotherapy, in whom the addition of glasdegib to LDAC nearly doubled the median overall survival compared with LDAC alone. (nih.gov)
  • Potential advances in combination chemotherapy for advanced testicular cancer. (ox.ac.uk)
  • In this study, we compare a chemotherapy-free ATRA and arsenic trioxide treatment regimen with the standard chemotherapy-based regimen (ATRA and idarubicin) in both high-risk and low-risk patients with acute promyelocytic leukaemia. (ox.ac.uk)
  • Those with ultra-high volume metastases will receive BOP/VIP, possibly randomised against another intensive chemotherapy schedule. (ox.ac.uk)
  • Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. (ox.ac.uk)
  • Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. (cdc.gov)
  • Treatment-related adverse events (all grades) of fatigue (63.2% v 30.0%), nausea (36.8% v 5.0%), rash (21.1% v 0%), and raised alanine aminotransferase (57.9% v 10%) were more common with rucaparib.CONCLUSIONMaintenance rucaparib, following platinum-based chemotherapy, extended PFS in DRD biomarker-selected patients with mUC and was tolerable. (ucl.ac.uk)
  • The present standard of care, chemotherapy and all-trans retinoic acid (ATRA), results in a high proportion of patients being cured. (ox.ac.uk)
  • In the present study, K-ras analysis draws the following conclusions: (1) K-ras point mutation frequency was higher in the surgery group (10 of 24 patients) than in the chemotherapy-surgery group (3 of 20 patients). (ox.ac.uk)
  • In patients with disseminated disease, chemotherapy or radiation provides symptom palliation. (medscape.com)
  • Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
  • How comparable the studies should be for combining their data, in terms of design, patient population, follow-up, and end-points, is discussed in the first part of this paper. (regionh.dk)
  • The objective of this study was to assess rationality and effectiveness of management of venomous snake bite following standard protocol - Standard treatment guidelines of Government of West Bengal and National snakebite management protocol of Government of India.Methods: This was a retrospective observational study of six months (May - October 2017) duration. (who.int)
  • In more advanced cases, radiation combined with chemotherapy is the current standard of care. (medscape.com)
  • BT-ON014 trade name] treatment should only be initiated by a health care provider experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a health care provider only. (who.int)
  • Pancreatic cancers contain exclusively tumorigenic cancer stem cells (CSCs), which are highly resistant to chemotherapy, resulting in a relative increase in CSC numbers during gemcitabine treatment. (nih.gov)
  • See also Cervical Cancer Treatment Protocols . (medscape.com)
  • The practice of snake bite management is found to be adherent with standard protocol. (who.int)
  • The trial protocol is available at http://www.nejm.org/doi/suppl/10.1056/NEJMoa1111961/suppl_file/nejmoa1111961_protocol.pdf. (mcmaster.ca)
  • Preclinical studies suggested that glasdegib could sensitize AML cells to chemotherapy. (nih.gov)

No images available that match "antineoplastic combined chemotherapy protocols"